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Abstract 
Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) is a mitochondrial enzyme involved 
in fatty acid β-oxidation and the regulation of β-cell insulin secretion. Its role in insulin 
secretion became apparent in 2001 when the first report linking SCHAD deficiency with 
congenital hyperinsulinism of infancy (CHI) was published. Since then research into the 
mechanism of SCHAD-CHI has led to the view that SCHAD serves a β-cell specific function 
and that the mechanism involves inhibition of glutamate dehydrogenase. In this thesis, we 
studied functional differences of pathogenic and non-pathogenic SCHAD missense variants, 
investigated the β-cell specificity of SCHAD deficiency in an animal model, and sought to 
identify novel interaction partners of the protein.  
In Paper 1, we found that missense SCHAD variants occurring in datasets from human 
populations mostly behaved like the wild type protein, whereas CHI-associated SCHAD 
variants had altered properties with regard to protein stability, enzymatic function and 
interaction with GDH. Four of the seven studied CHI variants showed reduced protein 
expression when expressed in HEK293 cells. The remaining three pathogenic variants had 
stable expression but reduced enzymatic activity and binding to GDH.  
In Paper II, we generated conditional SCHAD knockout mice and studied the cell-type specific 
effects of SCHAD deficiency in β-cells and hepatocytes. We noted that the SCHAD protein 
was highly expressed in pancreatic β- and -cells, but virtually absent from the α-cells. The 
mice harboring a β-cell-specific deficiency in SCHAD expression were hypoglycemic under 
various conditions, and their islets were sensitive to amino acid-stimulated insulin secretion. 
Analysis of the transcriptome of isolated SCHAD knockout islets identified global changes in 
expression of genes involved in metabolism and β-cell identity. Overall, this study strengthened 
the hypothesis that SCHAD serves a specific function in the β-cells and that β-cell SCHAD 
deficiency is sufficient to cause hypoglycemia. 
In Paper III, we sought to identify novel protein interactions partners of SCHAD by performing 
a yeast two-hybrid screen in a library from human islets of Langerhans. We identified keratin 
8 (K8) as a putative binding partner and found additional evidence of an interaction by co-
immunoprecipitation experiments. We also analyzed SCHAD expression in a K8 knockout 
mouse and K8 expression in the SCHAD knockout mouse. However, the lack of one potential 
interaction partner did not affect expression of the other, except when K8 knockout mice were 
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fed a ketogenic diet. The dietary challenge resulted in an upregulation of SCHAD in the 
pancreas of WT animals and this was blunted in the absence of K8. More experiments need to 
be carried out in order to explore the possible biological relevance of the proposed SCHAD-
K8 interaction. 
In summary, this thesis increased our knowledge on the impact of missense variants on SCHAD 
function and may therefore aid in the clinical evaluation of rare variants found in patients with 
phenotypes related to β-cell function. We developed a new mouse model for SCHAD-CHI, 
which highlighted the importance for SCHAD expression in the β-cell as well as the 
heterogeneous expression of the enzyme in islet cell populations. Lastly, we found evidence 
for a novel and surprising protein interaction of SCHAD with K8 that remains to be further 
validated. 
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1.1. The human and mouse pancreas  
The pancreas serves dual roles in the endocrine and digestive systems of vertebrates. The 
endocrine pancreas secretes hormones into the blood stream that regulate glucose homeostasis, 
and the exocrine pancreas produces and secretes digestive enzymes into the duodenum to aid 
digestion. 
The human pancreas is an organ of approximately 14 – 18 cm length, weighing between 50 to 
100 g. It is commonly divided into a head, body and tail region. The head of the pancreas 
aligns with the C-bend of the duodenum. The body stretches horizontally below the stomach 
















Figure 1 Anatomic comparison of the human and mouse pancreas. (A) The human pancreas stretches from 
the C-bend of the duodenum to the spleen and is usually divided into three regions: head, body, and tail. (B) The 
mouse pancreas is structurally less defined but can also be divided into three regions: the duodenal, splenic, and 
gastric lobes. Homology in pancreas structure between man and mouse is indicated by color. Ducts are 
represented as full black lines going through the pancreas. Adapted from (1).    
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The mouse pancreas has a more diffuse morphology but can still be divided into three major 
lobes. The duodenal lobe is analogous to the head of the human pancreas and lies embedded 
in the mesentery around the duodenum. The splenic lobe is the largest part of the mouse 
pancreas and equivalent to the body and tail of the human pancreas. The smallest part of the 
mouse pancreas, the gastric lobe, extends upwards from the splenic lobe attaches to the 
stomach. This part may be analogous to the pyramidal process, a structure seen in only 50% 
of human pancreata (Figure 1B) (1). 
1.1.1. The endocrine pancreas - islets of Langerhans  
The endocrine pancreas consists of micro-organs called islets of Langerhans that are 
embedded in the exocrine parenchyma. These islets constitute up to 15% of the pancreas 
volume in neonates but this fraction decreases to 2 – 3% in adults (2).  
The islets of Langerhans contain five distinct endocrine cell types that originate from a 
common progenitor cell expressing neurogenin 3 (Ngn3) (3): the glucagon-secreting α-cell, 
the insulin-secreting β-cell, the somatostatin (SST)-secreting δ-cell, the pancreatic 
polypeptide-secreting PP-cells and the ghrelin-secreting ε-cells. β-cells form the largest group 
of islet cells and contribute to 50-70% of islet cell mass in humans and 60-80% in mice. Alpha 
cells are the second most abundant cell type, comprising 20 – 40% of islet cells in humans and 
10 – 20% in mice, followed by δ-cells which contribute 5 – 10%. PP-cells form only around 
5% of islet cells, but the posterior head of the human pancreas contains a specific subset of 
islets that are enriched in PP-cells and low in α- and β-cells. ε-cells are the least frequent cell 
type comprising 1% of total islet cells.  
In the mouse, islets are mostly organized in rounded or oval structures, in which a cluster of 
β-cells is surrounded by a mantle of other islet cells (Figure 2A,B). Human islets are overall 
more complex in architecture and non-β-cells are frequently observed in the islet core (Figure 
2C,D). The islets are distributed heterogeneously throughout the pancreas. In humans the tail 
of the pancreas has the highest density of islets per unit volume. In the mouse, the gastric lobe 
contains the highest and the splenic lobe the lowest number of islets per unit of tissue volume 
(1). Pancreatic islets are strongly perfused (Figure 2B,D). Even though they comprise only 2-
3% of the pancreas tissue mass, they receive up to 20% of pancreatic blood supply originating 













into the hepatic portal vein. Blood supply from the splenic artery ensures that islet cells receive 
systemic stimuli such as glucose and amino acids for hormone secretion (4). 
Besides from inputs via the blood supply, the islet receives stimuli from sympathetic, 
parasympathetic, and additionally in the mouse, cholinergic nerves (Figure 2B,D). Mouse 
islets are highly innervated, and the nerves make direct contact with the endocrine cells. In 
humans, innervation is less pronounced and the nerves make contact with smooth muscle cells 
instead of endocrine cells (4).   
1.1.2. The insulin-secreting pancreatic β-cell 
The β-cells are the best studied of the five islet cell types and, together with the less numerous 
α-cell, they play a central role in the regulation of glucose homeostasis. β-cells have a 
polygonal shape and contain about 10,000 granules that store insulin as Zn2-insulin6 crystals. 
These granules have an electron-dense core with clear edges and a surrounding electron-lucent 
ring on electron microscopy images of islets.   
Figure 2. Structure and composition of the mouse and human islet of Langerhans. (A) 
Immunohistochemistry of a mouse islet stained for insulin (red), glucagon (green) and somatostatin (blue). (B) 
Schematic of mouse islet composition showing β-cells (red), α-cells (green) and δ-cells (blue), innervation and 
blood supply. (C) Immunohistochemistry of a human islet. Colors are the same as in (A). (D) Schematic of 
human islet. Colors are the same as in (B). Scale bars in (A) and (C): 20 μm. Adapted from (4) 
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The main function of β-cells is the secretion of the hormone insulin in response to an increase 
in blood glucose levels. Insulin is encoded by the INS gene. The mRNA first yields 
preproinsulin which undergoes cleavage to proinsulin upon entry into the endoplasmic 
reticulum (ER). Proinsulin contains a carboxy-terminal A chain and an amino-terminal B chain 
separated by stretch of amino acids called the C-peptide. Once it arrives in the Golgi apparatus, 
proinsulin is packaged into secretory vesicles. Here, the C-peptide is excised from the 
precursor to yield mature insulin and free C-peptide (5).  
Insulin is secreted in response to neurotransmitters, incretins (e.g. glucagon-like-peptide 
(GLP-1), gastric inhibitory polypeptide (GIP)), and nutrients such as glucose and amino acids. 
The regulation of insulin secretion will be discussed in detail in Chapter 1.2. However, the 
main stimulus is hyperglycemia, and insulin’s major function is to reduce increased blood 
glucose levels to normoglycemic levels. This is achieved by stimulation of glucose uptake in 
muscle and adipose tissue, stimulation of glycogen synthesis, glycolysis, and conversion of 
pyruvate to Acetyl Co-A (for ATP production in the Krebs cycle or fatty acid synthesis). 
Insulin also inhibits glycogen breakdown and gluconeogenesis.  
Besides glucose metabolism, insulin also influences lipid metabolism and protein synthesis. 
In liver and adipose tissue, insulin stimulates fatty acid synthesis, inhibits fatty acid β-
oxidation, and increases formation and storage of triglycerides. It also stimulates cholesterol 
synthesis. Insulin affects gene expression throughout the body. Some examples include 
augmentation of liver glucokinase, fatty acid synthase and albumin, and adipose tissue 
pyruvate carboxylase expression (6). Lastly, β-cells interact with local islet cell populations 
through autocrine and paracrine mechanisms. Insulin regulates β-cell mass, insulin synthesis 
and β-cell calcium flux. Insulin, zinc ions and gamma-aminobutyric acid (GABA), which are 
co-secreted with insulin, reduce glucagon secretion from α-cells (7).  
1.1.3. Other islet cell types 
α-cell 
α-cells are located in the islet periphery surrounding the β-cell core. In humans, α-cells may 
also be found within the core, lining arterioles and capillaries (4). α-cells secrete glucagon, 
which together with insulin regulates blood glucose levels. Glucagon is produced by cleavage 
of preproglucagon by prohormone convertase 2. Other cell types such as the L-cells in the 
5 
 
gastrointestinal tract, also produce the preproglucagon but process the precursor protein to 
yield GLP-1 and other hormones (8).  
In many ways, glucagon functions opposite of insulin. The hormone stimulates hepatic 
glycogenolysis and gluconeogenesis during hypoglycaemic conditions to increase hepatic 
glucose release and achieve normoglycemia. Glucagon also stimulates lipolysis and increases 
energy expenditure. Within the islet, glucagon has paracrine functions to stimulate insulin and 
SST secretion (8,9).  
The regulation of glucagon secretion is not as well defined as insulin secretion from β-cells. 
Studies suggest that glucagon secretion is regulated by glucose and amino acid levels, as well 
as paracrine factors. During low glucose conditions, ATP-sensitive potassium channels (KATP-
channels) are activated to generate a membrane potential of 60 mV. This opens low voltage-
gated calcium channels, and subsequently sodium and high voltage calcium channels. The 
influx of calcium then induces the exocytosis of glucagon granules. During high glucose 
conditions, ATP production increases which results in closure of KATP channels and inhibits 
glucagon secretion. However, high glucose has been reported to potently stimulate glucagon 
secretion from isolated alpha cells, an effect that is absent in intact islets. In whole islets, 
glucagon secretion under high glucose conditions may be suppressed through paracrine action 
of insulin, SST, zinc ions and GABA (9,10). 
δ-cell 
δ-cells can also be found in the CNS and scattered throughout the gastrointestinal tract. In 
mouse islets, δ-cells mostly surround the core, with few cells being located in the islet center. 
In humans, δ-cells may be found scattered throughout the islet. δ-cells make tight contact with 
several α- and β-cells through neurite-like processes and negatively regulate insulin and 
glucagon secretion through secretion of SST and β- to δ-cell electrical coupling. β- and δ-cells 
share an immediate common progenitor and δ-cells have been reported to transdifferentiate 
into β-cells. Both cell types share common properties related to their secretory function such 
as the expression of glucokinase and KATP channel genes (ABCC8 and KCNJ11). Stimulants 
of SST secretion also include glucose, amino acids (leucine and arginine), neurotransmitters, 
hormones such as GABA, glucagon, GLP-1, ghrelin, urocortin 3, and possibly insulin. 
However, SST secretion is initiated at lower glucose levels than insulin secretion (3 vs. 6 mM 
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in the mouse) and contrary to α- and β-cells, δ-cell SST secretion is inhibited by palmitate. 
SST secretion is also inhibited by adrenaline and possibly by SST itself (11). 
PP-cell 
Most of the PP-cells are concentrated in the head of the pancreas. In mice, the majority of PP-
cells, like α- and δ-cells, are found surrounding the islet core. In human islets, PP-cells are 
located in close proximity to blood vessels. Some PP-cells can also be found scattered 
throughout the exocrine parenchyma of the pancreas. They postprandially secrete pancreatic 
polypeptide (PPY) in response to vagus and enteric nerve stimulation and increased levels of 
amino acids (arginine). PPY negatively regulates gastric emptying as well as intestinal 
mobility and inhibits α-cell glucagon secretion under hypoglycemic conditions (8). 
ε-cell 
ε-cells are the least abundant islet cell type in adults but make up to 10% of the islet cells mass 
in neonates. Like other non-β-cells, most ε-cells are located in the islet periphery of mouse 
islets. Some ε-cells may also be found in pancreatic ducts or scattered throughout the exocrine 
parenchyma (12). They, in concert with P/D1 cells in the gastric fundus, produce the “hunger 
hormone” ghrelin as response to fasting and as hunger levels rise. Ghrelin acts in the central 
nervous system as a signal to initiate food intake and plays widespread systemic roles in the 
regulation of glucose homeostasis, energy expenditure and body weight development (13). It 
also plays a local role within the islet, as a paracrine inhibitor of insulin secretion during 
fasting. Even though ε-cells make a minor contribution to islet mass, evidence suggests that 
they are a significant source of circulating ghrelin in humans (12).  
1.1.4. The exocrine pancreas 
The exocrine parenchyma constitutes about 90% of the pancreas volume and contains acinar, 
stellate, and ductal cells. Acinar cells are specialized cells that synthesize and secrete digestive 
enzymes which are transported to the intestine through a network of pancreatic ducts. Acinar 
cells are characterized by a highly basophilic cytoplasm, basally located nucleus, and apically 
located secretory granules. They are organized in small clusters called acini which surround a 
lumen that connects to intercalating ducts. These ducts drain into intralobular ducts and further 
into interlobular ducts which open into the pancreato-hepatic duct. Ductal cells aid in the 
transport of the digestive enzymes by secreting bicarbonate and water which mix with the 
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enzymes and form the pancreatic juice. The stellate cell is the least numerous cell type within 
the exocrine pancreas. These cells uphold pancreas structure by regulating the formation and 
degradation of extracellular matrix and are central players in fibrotic processes in pancreatic 
exocrine disease (14).  
Although the exocrine and endocrine pancreas generally have been treated as two separate 
organ compartments, there is now increasing evidence of endocrine-exocrine crosstalk and 
interdependence. Blood flow between the islets and exocrine tissue is interconnected allowing 
for paracrine regulation in either direction (15). Exocrine cells are exposed to high levels of 
islet hormones which serve as regulators of exocrine secretion (16). Moreover, the two 
compartments are not separated and are in intimate physical contact with each other. Peri-islet 
acinar cells in close contact with islet cells are morphologically and functionally different from 
the more distantly located tele-islet acinar cells. Evidence suggests crosstalk between islets 
and peri-islet acinar cells plays a role in islet expansion in diabetes (17). 
Due to the interconnectedness of the endocrine and exocrine pancreas it is not surprising that 
dysfunction in either compartment has implications for the other. Indeed, exocrine dysfunction 
as seen in conditions such as chronic pancreatitis, cystic fibrosis and maturity-onset diabetes 
of the young type 8 (MODY8), is a risk factor for endocrine dysfunction and type 3c diabetes 
(18). On the other hand, diabetes has been found to be a risk factor for and to exacerbate acute 
pancreatitis (19) and there are links between diabetes and pancreatic cancer (20). 
 
1.2. The regulation of insulin secretion 
1.2.1. Glucose-stimulated insulin secretion 
The postprandial rise in blood glucose levels is the most important physiological stimulus for 
insulin secretion (Figure 3). Glucose enters the β-cell via facilitated, insulin-independent 
transport. In humans, this is primarily mediated by the membrane protein solute carrier family 
2 member 1 (GLUT1) and to a lesser extent solute carrier family 2 member 3 (GLUT3). 
Rodents mainly utilize solute carrier family 2 member 2 (Glut2) (21). The difference in 
glucose transporter expression may explain the distinct set points of normoglycemia in human 
and mouse. Humans maintain their blood glucose levels around 90 mg/dl and mice around 140 
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mg/dL (22). GLUT1 and GLUT3 have lower Km for glucose transport than Glut2 (6 mM and 
1 mM vs. 11 mM), allowing for glucose transport at lower blood glucose levels (21). 
After glucose enters the β-cell, it is converted to glucose-6-phoshate by glucokinase (GK), the 
glucose sensor of the β-cell. GK belongs to the hexokinase superfamily and is expressed in the 
β-cell, liver, and brain (23). Like other hexokinases, it catalyzes the conversion of glucose to 
glucose 6-phosphate (G6P). However, contrary to other hexokinases, GK is not inhibited by 
its product (24). Furthermore, glucokinase remains in an inactive configuration during low 
glucose conditions and as glucose levels rise, the substrate stimulates the switch to its active 
state (25). These attributes ensure low G6P production when blood glucose levels are low and 
high G6P production as glucose levels rise.  
G6P subsequently serves as substrate for glycolysis and the TCA cycle, leading to a rise in 
ATP and a decrease in ADP levels. This change in β-cell energy status stimulates the closure 
of KATP-channels. When the β-cell is not stimulated, the KATP channel transports potassium 
ions out of the cell to maintain a resting potential. Closure of the KATP channel stops the export 
Figure 3. Insulin secretion in response to glucose and amino acids. Glucose enters the β-cell via facilitated 
transport through GLUT1 and GLUT3 (in the mouse Glut2). Glucokinase (GK) converts glucose to glucose-6-
phosphate (G6P). G6P metabolism results in ATP production from the TCA cycle, a rise in the ATP:ADP ratio 
and closure of ATP-sensitive potassium channels (KATP-channel). This in turn blocks the export of positively 
charged potassium ions (K+) and causes the loss of negative charge that triggers depolarization of the β-cell 
membrane. Voltage gated calcium channels (VGCC) then open to allow influx of calcium ions (Ca2+). Finally, 
the import of Ca2+ stimulates exocytosis of insulin granules. Amino acids enter the cell through cationic or sodium 
coupled amino acid transporters and enhance insulin secretion via evocation of a depolarization current and 
metabolism in the TCA cycle which may be stimulated by glutamate dehydrogenase (GDH) activity.  
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of the positively charged potassium ions, which in turn causes a loss of negative charge and 
subsequent depolarization of the β-cell plasma membrane (26). 
Membrane depolarization then stimulates the opening of voltage gated calcium channels 
(VGCC). Opening of VGCCs then allows for an influx of calcium ions which in turn trigger 
the fusion of the secretory granule with the plasma membrane in a process similar to 
neurotransmitter release (27).  
The fusion of insulin granules with the β-cell plasma membrane is mediated by the SNARE 
complex. The SNARE complex is composed of soluble N-ethylmaleimide-sensitive factor 
attachment protein (SNAP) receptor proteins (SNAREs) and Sec1/Munc18-like (SM) 
proteins. Important SNARE proteins of the SNARE complex are the plasma membrane bound 
synaptosomal-associated protein of 25 kDa (SNAP-25) and syntaxin-1, as well as Vesicle 
Associated Membrane Protein 2 (VAMP) that is integrated into the insulin granule membrane. 
Insulin granule exocytosis is initiated by binding of calcium to synaptotagmin proteins within 
the vesicle membrane which then interact with SNAREs to facilitate membrane fusion (26). 
Insulin release occurs in two phases. The β-cell contains ca. 10.000 mature insulin granules 
that are either pre-docked at the plasma membrane or stored deeper in the cell. First phase 
insulin secretion peaks between 3-5 minutes after stimulation and rapidly releases a small, pre-
docked subset of insulin granules through the mechanism described above. Insulin secretion 
in the second phase is slower (5 – 40 granules/min) but can be sustained for long periods of 
time until normoglycemia has been achieved (28). Interestingly, while first phase insulin 
secretion can be stimulated by non-nutrient stimuli such as KCl, second phase insulin secretion 
is dependent on nutrients such as glucose (29). 
1.2.2. Insulin secretion stimulated by other nutrients 
Amino acids and lipids modulate insulin secretion in the presence of glucose. Amino acids 
enter the β-cell through cationic amino acid transporters and sodium-coupled neutral amino 
acid transporters (Figure 3). They are capable of evoking mild depolarization currents either 
by providing a positive charge themselves (e.g. arginine and lysine) or by requiring co-
transport of positively charged sodium ions (e.g. alanine and glutamine). Uptake of these 
amino acids triggers depolarization in the presence of glucose, especially when glucose 
stimulation is mild and KATP-conductance is low (4). Additionally, alanine, glutamate, and 
glutamine serve as substrates for the TCA cycle. Their metabolism therefore increases the 
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ATP:ADP ratio to promote plasma membrane depolarization via closure of the KATP-channels 
(30). Glycine is co-secreted with insulin and serves as an autocrine potentiator of insulin 
secretion. It binds to ionotropic glycine receptors and triggers an influx of chloride ions which 
in turn leads to membrane depolarization (4). 
Leucine plays a unique role in the stimulation of insulin secretion. It is the only amino acid 
that is capable of initiating insulin release independent of glucose action. It can serve as 
substrate for metabolism and ATP production, but it also stimulates the production of ATP via 
the TCA cycle by allosteric activation of glutamate dehydrogenase (GDH) (4). 
Non-esterfied fatty acids acutely stimulate insulin secretion from isolated islets. Chronic 
incubation, on the other hand, negatively regulates insulin secretion. The mechanism 
underlying stimulation of insulin secretion by these fatty acids and its biological relevance are 
not fully elucidated. One suggested mechanism involves binding to free fatty acid receptor 1 
on the β-cell surface. This leads to an influx of calcium ions and depolarization of the plasma 
membrane, thereby potentiating glucose-stimulated insulin secretion (4).  
1.2.3. Paracrine regulation of insulin secretion by α- and δ-cells 
α-, β-, and δ-cells form a tight network that regulates hormone secretion via paracrine 
mechanisms (Figure 4). β-cells suppress glucagon secretion from α-cells via paracrine action 
of insulin and other secreted factors (serotonin (5-HT), GABA, zinc ions). Conversely, β-cells 
stimulate SST secretion from δ-cells primarily via urocortin-3, which is co-secreted with 
insulin (30).  
Glucagon derived from α-cells potentiates insulin secretion via binding to glucagon receptor 
(GCGR) and the related glucagon-like peptide receptor (GLP1R). Additionally, human α-cells 
secrete corticotropin-releasing hormone (CRH) and acetylcholine. Mouse α-cells neither 
secrete CRH (although mouse β-cells express the corresponding receptor), nor acetylcholine. 
Acetylcholine in mouse islets originates from parasympathetic neurons which make tight 
contact with endocrine cells (see Chapter 1.1.1). CRH and acetylcholine both potentiate insulin 
secretion directly by acting on β-cells via signaling through corticotropin-releasing hormone 
receptor 1 (CRHR1) and muscarinic acetylcholine receptor M3 (CHRM3), respectively. 
Additionally, acetylcholine inhibits SST secretion by binding to muscarinic acetylcholine 










Finally, δ-cells provide tonic inhibition of insulin and glucagon release from α- and β-cells. 
They secrete SST in response to glucose in a manner similar to glucose-stimulated insulin 
secretion (see Chapter 1.1.2). SST signals through somatostatin receptors (SSTR). SST 
prevents excess secretion of insulin and may be responsible for low glucagon secretion at high 
glucose levels, thereby providing important regulatory input for both α- and β-cells (30). 
1.2.4. Other modulators of insulin secretion 
Maintenance of glucose homeostasis involves a network of highly specialized cell types not 
only in the pancreas, but also within organs such as the brain, gastrointestinal tract, liver, 
adipose tissue, and muscle. Appropriate insulin secretion therefore requires input from these 
tissues. 
Stimuli such as the smell or sight of food trigger the cephalic phase of insulin secretion that 
initiates insulin secretion before a meal. This mechanism is mediated by the autonomous 
nervous system via cholinergic and non-cholinergic stimulation and prepares the organism for 
food intake (31). Besides initiating insulin secretion, the autonomous nervous system 
modulates glucose-dependent insulin secretion. Pancreatic islets are highly innervated with 
Figure 4. Paracrine interaction between α-, β-, and δ-cells. α-cell and α-cell-derived factors are indicated in 
yellow, β-cell and β-cell-derived factors in blue and δ-cell and δ-cell-derived factors in green. During 
hyperglycemia, β-cells secrete insulin, serotonin (5-HT), GABA and zinc ions, all of which suppress glucagon 
secretion from α-cells. α-cells on the other hand augment glucose-dependent insulin secretion by secretion of 
glucagon, acetylcholine (Ach) and corticotropin-releasing hormone (CRH). δ-cells negatively regulate both α- 
and β-cells via secretion of somatostatin (SST). β-cells stimulate SST secretion from δ-cells in a negative 
feedback loop by co-secretion of urocortin-3 with insulin. Finally, α-cell-derived ACh inhibits SST release from 
δ-cells. Drawn after (30). 
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sympathetic and parasympathetic neurons (see Chapter 1.1.1), and neuron-derived factors, like 
norepinephrine and neuropeptide Y (NPY), are inhibitors while other neuropeptides such as 
pituitary adenylate cyclase-activating polypeptide and gastrin releasing peptide are stimulators 
of insulin secretion (26). 
Up to 50% of insulin secretion after a meal is attributable to the incretin effect mediated by 
GLP-1 and GIP.  These hormones are secreted in response to a mixed meal by gastrointestinal 
L- and K-cells, respectively. Both stimulate glucose-dependent insulin secretion by binding to 
their respective receptors on β-cells (GLP1R and GIPR). This initiates a signaling cascade that 
augments insulin secretion via increasing the insulin granule density at the plasma membrane, 
stimulating flux of calcium ions from internal stores into the cytoplasm, and modulating KATP-
channel and calcium channel activity. Besides influencing insulin, GLP-1 inhibits, and GIP 
enhances glucagon release from α-cells. The gut also secretes decretins which inhibit insulin 
release during a fast. One of these, neuromedin U, suppresses insulin release directly in β-cells 
by signaling through its receptor (NmUR1) and possibly through stimulation of SST secretion 
(26).  
Adipose tissue and muscle are highly regulated by insulin-dependent glucose uptake through 
GLUT4 and insulin signaling in general. In turn, adipocytes and myocytes secrete factors that 
modulate β-cell function underscoring the importance of inter-organ cross talk. Adipose tissue 
secretes the well-known hormones leptin and adiponectin that have opposite effects on insulin 
secretion. Leptin inhibits insulin secretion by reducing insulin gene expression and activation 
of KATP-channels. Adiponectin signaling, on the other hand, improves β-cell survival, insulin 
gene expression and secretion. Adipocytes and myocytes secrete interleukin 6 (IL-6), which 
influences insulin secretion indirectly via augmentation of glucagon secretion from α-cells and 
GLP-1 secretion from gastrointestinal L-cells (26).  
 
1.3. Congenital hyperinsulinism of infancy 
1.3.1. Definition and symptoms of CHI  
CHI designates a group of genetically different disorders that are characterized by non-ketotic 
hypoglycemia and inappropriately elevated insulin secretion. It is a rare, inherited condition 
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with an incidence of 1:30,000 in northern Europe (32). However, in areas with high level of 
consanguinity, the incidence can rise up to 1:2,500 (33). 
CHI is one of the most common causes of hypoglycemia in newborns and infants and poses a 
risk for the development of permanent brain damage. The condition is caused by mutations in 
genes that are involved in the regulation of insulin secretion and may manifest as a focal lesion 
or affect all β-cells within the pancreas. The symptoms range from mild to severe depending 
on the underlying mutation and form of CHI, making early diagnosis a necessity to prevent 
permanent neurological affection or even life-threatening hypoglycemia (34).  
The hypoglycemia of CHI is most often transient but can also be persistent. Depending on 
which gene is mutated, low blood sugar levels can be elicited by fasting, protein-rich meals or 
exercise, or a combination of some of these. Symptoms are mostly related to the hypoglycemia 
and may range from increase or loss of appetite, pallor, sweating, and heart palpitations to 
seizures, unconsciousness, coma, and even death. Some forms of CHI present with increased 
birthweight (34). Moreover, some CHI forms are characterized by specific physiological 
defects that may aid in their diagnosis. One example is the occurrence of hyperammonemia in 
patients with activating mutations in GLUD1 (35). 
Besides being the hallmark of CHI, hyperinsulinemic hypoglycemia can be part of syndromes 
presenting with several functional and congenital anomalies. These syndromes include 
overgrowth disorders such as Beckwith-Wiedemann (36) and Sotos (37) syndrome, or 
multisystem disorders such as Kabuki (38) and Turner (39) syndrome.  
1.3.2. Histological differentiation of CHI subtypes 
CHI can be classified histologically into three forms: diffuse, focal and atypical CHI. The 
majority of CHI cases (60%) belong to the diffuse form, which affects the function and 
morphology of all β-cells in the pancreas (34). Focal CHI usually occurs sporadically and is 
caused by inheritance of a paternal loss-of-function mutation in ABCC8 or KCNJ11 together 
with somatic loss of the maternal allele (see below). This leads to proliferation of the affected 
β-cells and increased insulin secretion from the developing focal lesion (40). Atypical CHI 
does not fit the histological criteria of diffuse or focal CHI. This form is characterized by 
heterogeneous populations of islets. Some islets appear hyperactive with β-cells that contain 
large nuclei and cytoplasm, distinctive of increased hormone production, while other islets 
appear small and quiescent (34,41). 
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1.3.3. Genetic causes of CHI 
Mutations in around 15 different genes have been reported to cause CHI (42), and the disease 
can be categorized in three groups based on the type of affected gene (Table 1; Figure 5). The 
first group is associated with mutations in channel and transporter proteins. This group, 
classically referred to as channelopathies, includes mutations in the genes that encode the 
subunits of the β-cell KATP channel, ABCC8 and KCNJ11. Other channel and transporter genes 
implicated in CHI that can be classified as channelopathies are CACNA1D, KCNQ1 and 
SLC16A1 (42). 
Table 1. Subgroups and molecular causes of CHI. D = autosomal dominant inheritance, R = autosomal 
recessive inheritance, IM = inactivating mutations, AM = activating mutations. 
 Gene Encoded protein Inheritance Mutation  
Channelopathies ABCC8 Sulfonylurea receptor-1 (SUR1) D/R  IM 
 KCNJ11 Inward rectifier K+ channel (Kir6.2)  D/R  IM 
 CACNA1D Voltage-dependent L-type calcium 
channel subunit alpha-1D (CACNA1D) 
Sporadic AM 
 KCNQ1 potassium voltage-gated channel 
subfamily KQT member 1 (KvLQT1) 
D IM 
 SLC16A1 Monocarboxylate transporter 1 (MCT1)  D AM 
Metabolopathies GCK Glucokinase (GCK)  D AM 
 GLUD1 Glutamate dehydrogenase (GDH)  D AM 
 HADH Short chain L-3-hydroxyaxyl-CoA 
dehydrogenase (SCHAD)  
R IM 
 HK1 Hexokinase (HK1)  D AM 
 PMM2 Phosphomannomutase 2 (PMM2) R IM 
 UCP2 Mitochondrial uncoupling protein 2 
(UCP2)  
D AM 
Transcriptionopathies HNF1A Hepatocyte nuclear factor 1 alpha (HNF-
1A)  
D IM 
 HNF4A Hepatocyte nuclear factor 4 alpha (HNF-
4A)  
D IM 
 FOXA2 Forkhead box A2 (FOXA2) Sporadic IM 
 
The second group are the metabolopathies. The regulation of insulin secretion depends on 
nutrient sensing and tight control of nutrient flux. Therefore, mutations that perturb the normal 
regulatory framework of β-cell metabolism may stimulate insulin secretion under 
inappropriate conditions such as hypoglycemia. The most well-established genes in this group 
are GCK, GLUD1 and HADH. Other members are HK1, PMM2 and UCP2. The HADH gene 
and its CHI-causing mutations are the main focus of this thesis and will be discussed in detail 
in Chapter 1.4. 
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The last and smallest group is characterized by mutations in transcription factors. Mutations 
in these genes affect β-cell metabolism due to altered transcriptional regulation. This group 
presently includes the HNF-1A, HNF-4A and FOXA2 genes (42). As mentioned above, for the 
first two CHI groups, the umbrella terms “channelopathy” and “metabolopathy” are used to 
describe unifying characteristics of their associated gene mutations and their influence on β-
cell biology. Since the common feature of the third CHI form is dysregulation caused by 
altered transcription factor activity, we propose to use the term “transcriptionopathy” to refer 
Figure 5. CHI-associated genes and their location in β-cell insulin secretion. Channelopathies are indicated 
in green, metabolopathies in blue and transcriptionopathies in yellow color. Channelopathies alter the transport 
of ions or metabolites across the β-cell plasma membrane. These are caused by mutations in the β-cell KATP 
channel subunits SUR1 and Kir6.2 L-type voltage-dependent Ca2+ channel (VGCC), the potassium voltage-
gated channel subfamily KQT member 1 subunit of an inwardly rectifying K+ channel (Kir7.1.) and 
inappropriate expression of monocarboxylate transporter 1 (MCT-1). Metabolopathies increase insulin secretion 
by altering β-cell metabolism. These are caused by mutations in glutamate dehydrogenase (GDH), glucokinase 
(GK), inappropriate expression of hexokinase 1 (HK1) and inactivating mutations of short-chain hydroxyacyl-
CoA dehydrogenase (SCHAD), uncoupling protein 2 (UCP-2) and phosphomannomutase 2 (PMM2). 
Transcriptionopathies includes transcription factors that regulate expression of genes important for β-cell 





to this subgroup. In the following subchapters, we will discuss the genetic etiology of CHI 
caused by channelopathies, metabolopathies, and transcriptionopathies. 
1.3.4. Channelopathies 
ABCC8/ KCNJ11 
The most common and often most severe form of CHI is caused by mutations of the β-cell 
KATP channel. The channel is a hetero-octamer formed by assembly of four subunits of 
sulfonylurea receptor-1 (SUR1) and four subunits of the inwardly rectifying potassium 
channel (KIR6.2) which are encoded by the genes ABCC8 and KCNJ11, respectively. The 
KATP channel plays a central role in the insulin secretion pathway (Figure 3) where it connects 
the energy state of the β-cell to insulin release by depolarization of the cell membrane, which 
subsequently activates voltage-gated calcium channels. Mutations in ABCC8 and KCNJ11 that 
perturb functional cell membrane expression of the KATP channel therefore lead to increased 
or continuous depolarization of the β-cell plasma membrane with subsequent stimulation of 
insulin release (42).  
Several types of these mutations in ABCC8 and KCNJ11 have been described:  
a) Recessive inactivating mutations that increase the turnover rate of SUR1 and KIR6.2, 
leading to complete absence of the KATP channel on the β-cell membrane in homozygous 
or compound heterozygous carriers (43). This is the most common subtype. 
b) Recessive mutations that disrupt trafficking of SUR1 and Kir6.2 (44).  
c) Recessive mutations that reduce KATP channel sensitivity to ADP, thereby allowing for 
ATP-mediated closure of the channel at lower ATP:ADP ratio (45). 
d) Dominant inactivating mutations leading to reduced function of the KATP channel. These 
mutations usually cause the mildest form of KATP channel-CHI and sometimes transition 
to a diabetic phenotype later in life (46). This is a very rare subtype. 
e) Focal CHI (described below) 
ABCC8 and less often KCNJ11 mutations also underlie the development of focal CHI. Focal 
CHI develops in response to multiple hits affecting the expression of KATP channel as well as 
multiple genes involved in cell proliferation. The first hit is paternal inheritance of a mutation 
in ABCC8 or KCNJ11 on chromosome 11. The second hit is somatic loss of the maternal 
region encompassing the KATP channel gene and multiple imprinted genes involved in cell 
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proliferation (CDKN1C, IGF-II and H19). The maternally expressed genes CDKN1C and H19 
are inhibitors of cell proliferation, while the paternally expressed IGF-II promotes cell growth. 
Loss of the maternal segment thus causes imbalance in the regulation of cell proliferation 
leading to focal hyperplasia. Lastly, duplication of the paternal segment of chromosome 11 
leads to isodisomy and homozygosity of the mutant KATP gene leading to dysregulated insulin 
secretion from the developing lesion (47).  
CACNA1D 
CACNA1D encodes the subunit alpha-1D of an L-type voltage-dependent Ca2+ channel 
(VGCC). Activating mutations in the gene are rare but have been described to force the 
channel into an open configuration at lower than normal membrane potential, leading to 
increased influx of Ca2+ ions and subsequent insulin secretion. Additionally, patients with 
activating mutations suffer from neuromuscular abnormalities, primary hyperaldosteronism, 
heart defects, and hypotonia (42,48). 
KCNQ1 
KCNQ1 encodes potassium voltage-gated channel subfamily KQT member 1 (Kir7.1), the 
pore-forming subunit of a potassium channel that mediates voltage-gated repolarization of the 
plasma membrane. KCNQ1 is expressed in cardiomyocytes, pancreatic β-cells, cells of the 
inner ear and in the gastrointestinal track. Loss-of-function mutations in KCNQ1 are associated 
with long QT syndrome, a group of conditions characterized by heart arrythmias caused by 
defective myocellular repolarization, syncope, deafness and sudden death (49). KCNQ1 is also 
expressed on β-cells and mutations have been linked to postprandial hyperinsulinemic 
hypoglycemia most likely due to prolonged depolarization of the β-cell membrane (50).  
SLC16A1 
SLC16A1 encodes the monocarboxylate transporter 1 (MCT-1), which transports pyruvate and 
lactate into cells. MCT-1 expression, and therefore pyruvate and lactate levels, are low in β-
cells. Normally, this prevents excessive ATP production and subsequent stimulation of insulin 
secretion during and after exercise, i.e. when blood levels of lactate are high. Dominant 
activating mutations in the promoter of SLC16A1 disrupt this regulation by causing 
overexpression of the transporter protein in the β-cells. This causes an excessive influx of the 
metabolites, especially after strenuous exercise, leading to inappropriately high insulin 
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secretion stimulated by pyruvate metabolism (42,51). This form of CHI has also been 
classified as exercise-induced hyperinsulinism. 
1.3.5. Metabolopathies 
GLUD1 
Dominant, activating mutations in GLUD1 cause the hyperinsulinism/hyperammonemia 
syndrome, the second most common form CHI (35). GLUD1 encodes the mitochondrial 
enzyme glutamate dehydrogenase (GDH) which is expressed at high levels in the pancreas, 
liver, kidney, and brain. The enzyme catalyzes the reversible conversion of glutamate to α-
ketoglutarate and ammonia using NAD+ or NADP+ as co-enzymes. GDH activity is modulated 
by allosteric inhibitors such as GTP and ATP and activators such as leucine and ADP (52). 
CHI-causing mutations in GLUD1 most commonly affect the sensitivity of GDH to its 
inhibitor GTP and lead to increased activity of the enzyme (53,54). In the β-cell, this is thought 
to lead to increased insulin secretion either through increased production of α-ketoglutarate 
which is then metabolized in the citric acid cycle to produce ATP or through increased 
production of glutamate which amplifies insulin secretion after uptake into insulin granules 
(55,56).  
The phenotype of GDH-CHI is usually milder compared with the disease caused by KATP 
mutations. Characteristic features are fasting-induced hypoglycemia and protein sensitivity 
due to the stimulatory effect of leucine on GDH activity. Besides the hyperinsulinism 
phenotype, a hallmark of GDH-CHI is hyperammonemia (usually asymptomatic) due to 
increased GDH activity in the kidney (57). This phenotype is unique amongst CHI conditions 
and may aid in the diagnosis of GDH-CHI. Some forms of GDH-CHI are also associated with 
epilepsy and developmental delay (35). 
GCK 
Glucokinase (GK), also known as hexokinase 4, is expressed by the GCK gene. As stated in 
Chapter 2.1, it functions as the β-cell glucose sensor by linking plasma glucose levels to ATP 
production to insulin release (23). Due to GK playing such a central role in the insulin secretion 
pathway, β-cells are highly sensitive to changes in its activity. Mutations that reduce GK 
activity cause chronic mildly elevated glucose (GCK-MODY or MODY2) (58). On the other 
hand, mutations that increase the affinity of the enzyme to glucose, mostly by altering its 
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allosteric activator domain, cause CHI. Here, glucokinase is active at lower than normal 
glucose concentrations, causing inappropriate insulin secretion (59).  
HK1 
Similar to GK, hexokinase 1 (HK1) belongs to the hexokinase superfamily and catalyzes the 
phosphorylation of glucose to G6P. Unlike GK, the affinity for glucose remains high in low 
glucose conditions for HK1. Therefore, expression of HK1 when glucose is scarce is 
disadvantageous in β-cells since it would allow for the stimulation of insulin secretion under 
unfavorable conditions. The β-cell thus has evolved to suppress expression of HK1 when 
glucose levels are low (60). Dominant mutations in the non-coding region of the HK1 gene 
may override the glucose-associated gene silencing at low glucose levels, allowing for 
inappropriate HK1 expression and stimulation of the insulin secretion pathway (61). 
PMM2 
Phosphomannomutase 2 is encoded by the PMM2 gene. It is involved in glycoprotein 
synthesis, thereby enhancing stability of its target proteins. Homozygous, recessive loss-of-
function mutations in PMM2 cause congenital disorder of glycosylation (CDG), a complex 
disorder of varying severity and with a wide spectrum of symptoms related to glycosylation 
defects (62). Some forms of this condition (CDG type 1b and less often CDG type 1a and 1d), 
have been linked to diazoxide-responsive hyperinsulinemic hypoglycemia. The exact 
mechanism behind CHI in patients with CDG is still unclear, and hypoglycemia in CGD type 
1a may also occur in the absence of hyperinsulinism (63). 
UCP2 
Inactivating mutations in UCP2 are associated with CHI of varying severity. UCP2 encodes 
mitochondrial uncoupling protein 2 (UCP-2), a member of the inner mitochondrial anion-
carrier family. The protein plays a role in uncoupling of oxidative phosphorylation from ATP 
production. Loss of UCP2 expression in β-cells leads to an increase in ATP production from 






HNF1A and HNF4A 
Hepatocyte nuclear factor 1-alpha (HNF-1A) and hepatocyte nuclear factor 4-alpha (HNF-4A) 
are transcription factors of the nuclear receptor superfamily that control gene expression in 
several organs, including the liver and pancreatic islet (65). Amongst the regulated targets are 
genes involved in glucose-stimulated insulin secretion, such as KCNJ11 (66,67). 
Heterozygous inactivating mutations in HNF1A or HNF4A in humans can sometimes result in 
macrosomia and transient, mild and diazoxide-responsive CHI in newborns, although this 
phenotype always transforms into MODY3 and MODY1, respectively, later in life (66,68).   
FOXA2 
Forkhead box A2 (FOXA2) is a transcription factor involved in the development of endoderm-
derived tissues. In the pancreas, FOXA2 expression is necessary for normal organ 
development, due to its role in controlling PDX1 and other transcription factors that regulate 
differentiation of α- and β-cells (69,70). In the mouse, inactivating mutations in the Foxa2 
gene result in low numbers of α-cells and disproportionally large number of β-cells. 
Furthermore, FOXA2 also regulates expression of other CHI-associated genes, such as 
ABCC8, KCNJ11 and HADH (71) which are down-regulated in patients with mutant FOXA2 
(72). The clinical phenotype of patients with FOXA2 mutations has been described to include 
hyperinsulinemic hypoglycemia, congenital hypopituitarism, as well as craniofacial 
dysmorphism and developmental defects in the brain (pituitary, corpus callosum), liver, lung, 
gastrointestinal tract (72,73).  
1.3.7. Diagnosis and treatment of CHI 
Hypoglycemia with detectable plasma insulin and C-peptide is the hallmark of CHI. The exact 
definition of which level of plasma glucose is hypoglycemia has been widely debated, but the 
most common plasma glucose levels to define hypoglycemia are ≤ 50 mg/dL (2.8 mmol/L) or  
≤ 45 mg/dL (2.5 mmol/L). It is not unusual for insulin and C-peptide to be low or undetectable 
in neonates and infants, and the severity of hypoglycemia does not correlate with measured 
blood insulin levels (74,75). Moreover, transient hypoglycemia in neonates is very common, 
and the severity and persistence of hypoglycemia will alert the caring physician to suspect 
CHI. Other markers may aid in the diagnosis of CHI. These include reduced plasma levels of 
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fatty acids and ketone bodies during hypoglycemia, and an increased glucose infusion 
requirement to maintain normoglycemia (76).  
Hypoglycemia in neonates with CHI is often severe and puts the child at risk for irreversible 
brain damage. The first measure, therefore, is to stabilize blood glucose levels by 
administration of glucagon and glucose. Besides improving blood glucose levels, both 
measures aid in the diagnosis of CHI if they have the desired positive effect on the patient’s 
condition. An elevated glucose infusion requirement above around 10 mg/kg/min to maintain 
normoglycemia is indicative of hyperinsulinism (77). Glucagon raises blood glucose levels by 
stimulating hepatic glucose output. Conditions such as glycogen storage disease (GSD) affect 
glycogen metabolism and impair hepatic glucose output, leading to hypoglycemia and 
rendering glucagon ineffective (78). A spike in blood glucose levels after glucagon 
administration thus rules out GSD. It supports the diagnosis CHI and is effective for treating 
the hypoglycemia (77).  
Genetic screening can identify the mutant gene in the patient and family members who might 
be carriers. This facilitates the development of a treatment plan and helps reach a prognosis 
for the patient and possible future siblings. Some specific forms of CHI may also be identified 
due to phenotypical characteristics such as protein sensitivity and hyperammonemia in GDH-
CHI, protein sensitivity and increased levels of 3-hydroxybutyryl-carnitine in blood and 3-
hydroxyglutaric acid in urine in SCHAD-CHI, and exercise sensitivity in MCT1-CHI (42). 
Macrosomia is a common feature in CHI caused by mutations in genes such as HNF1A and 
HNF4A (79), as well as ABCC8 (80). This phenotype most likely reflects the growth-
promoting effects of increased insulin levels in utero and shortly after birth (81). However, 
macrosomia does not occur in all cases of CHI caused by mutations in these genes, and other 
forms of CHI, such as SCHAD-CHI (82), are not necessarily associated with increased 
birthweight. Thus, although macrosomia may aid in the diagnostic work-up of CHI, normal or 
low birthweight is not an exclusion criterion for this diagnosis.  
Once the diagnosis of CHI is established, it needs to be determined whether the patient is 
presenting with focal or diffuse CHI. Focal CHI can be detected by 18F-fluoro-L-
dihydroxyphenylalanine (F-DOPA) PET scanning. This is a highly sensitive and accurate 
method for visualization of focal lesions due to enhanced uptake of F-DOPA by overactive 
compared to healthy β-cells (34). Patients with focal CHI are often unresponsive to drug-
mediated suppression of insulin secretion. However, in these patients surgical resection of the 
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focal lesion is a viable option, leading to a cure for the condition in most patients (77). The 
most effective way to determine whether F-DOPA PET scanning should be investigated or 
not, is to make a genetic diagnosis. If homozygous or compound heterozygous mutations in 
ABCC8 or KCNJ11 are present, a diffuse CHI is present and a F-DOPA PET is not indicated. 
If a paternal heterozygous mutation in ABCC8 or KCNJ11 is present, a F-DOPA PET is 
indicated if the condition is severe (i.e. injection medical treatment is necessary to maintain 
stable glucose levels). If a maternal heterozygous mutation in ABCC8 or KCNJ11 is present, 
a focal lesion is less likely although many pediatricians will still order a F-DOPA PET to rule 
out a focal subtype. 
The long-term treatment of CHI depends on the underlying mutation and severity of the 
disease. It usually involves medical intervention aimed to lower insulin secretion. The first 
approach is administration of the oral drug diazoxide. Diazoxide is a KATP channel activator 
(“channel opener”) that binds to the SUR1 subunits of the β-cell KATP channel. Unfortunately, 
patients with mutations that affect the function or expression of SUR1 or Kir6.2 tend to be 
unresponsive to the drug. The next-in-line option for treatment of diazoxide unresponsive CHI 
are somatostatin analogues such as octreotide. These compounds inhibit insulin secretion by 
signaling through somatostatin receptors. Octreotide must be administered by injection, three 
times a day or via an insulin pump, due to the short half-life of the drug. Long-acting analogues 
are also available, which can be administered by an injection every 4-6 weeks. Other 
treatments that may be beneficial in the management of CHI are the immunosuppressant 
sirolimus and dietary changes. Continuous feeding with long-branched sugars is a crucial part 
of the treatment in addition to or without treatment with drugs. In addition, uncooked corn 
starch or ketogenic diet are sometimes used (34,83). 
Surgery may be a last resort treatment for severe, drug-unresponsive diffuse CHI. Here, more 
than 95% of the pancreas will be removed, dramatically reducing the number of β-cells. While 
this procedure may improve glycemic control in some patients, many patients still experience 
hypoglycemia, while nearly all develop diabetes during or after puberty. 
1.3.8. Mouse models of CHI 
CHI-causing mutations alter the function or expression of genes involved in the regulation of 
insulin secretion. Consequently, studying the mechanisms behind the defects caused by these 
mutations offers unique insights into β-cell biology in health and disease. Mouse models are 
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an invaluable tool in this process. Thus, several transgenic and knockout (KO) mice have been 
developed for different CHI subgroups (Table 2). Some of these models such as 
overexpression of Slc16a1 and whole-body KO of Hadh capture aspects of the human 
phenotype quite well. Like humans, mice with Slc16a1 overexpression develop exercise-
induced CHI and both humans and mice with disrupted HADH gene have elevated levels of 
plasma 3-hydroxybutyrylcarnitine and urinary 3-hydroxyglutarate (84,85).  
Partial loss of one of the KATP channel genes, Abcc8 or Kcnj11, accurately mimics the human 
phenotype of KATP channel mutations. In mice, this has been achieved by heterozygous KO of 
either gene, or β-cell-specific expression of dominant negative Kir6.2 (Kir6.2[AAA] or G132S 
point mutation). The full loss of either Abcc8 or Kcnj11 on the other hand does not cause a 
clear hyperinsulinism phenotype. Instead Abcc8 KO and Kcnj11 KO mice are characterized 
by impaired insulin secretion (86,87,96,97,88–95). 
It may be possible that some KATP-channel function is necessary for a hyperinsulinism 
phenotype. In many humans with ABCC8 or KCNJ11 mutations, residual KATP channel 
expression is observed (45,98). Heterozygous KO of Abcc8 or Kcnj11, and expression of 
Kir6.2[AAA] result in a reduction in KATP channel expression of ~60% and ~70%, 
respectively. Therefore, these mice might be a more accurate model for the human condition 
than the homozygous Abcc8 or Kcnj11 KO mice.  
Moreover, some patients with KATP-channel mutations eventually develop diabetes, a 
phenotype seen in mice with the G132S point mutation in Kcnj11 (71,72,80). These mice are 
hyperinsulinemic in youth but become diabetic in adulthood and may thus serve as a model 
for the study of the progression from KATP-channel-CHI to diabetes.  
For some forms of CHI, mouse models exist, but no hyperinsulinemic phenotype has been 
described. This includes KO and transgenic models of Kcnq1 and Hnf1a KO mice. Kcnq1 KO 
animals mirror the human phenotype of long QT syndrome. No hyperinsulinism, but a 
decrease in plasma insulin and glucose levels has been reported. However, these mice had 
been published before the association of Kcnq1 mutations with CHI was discovered (2001 and 
2009 vs. 2014) (50,100,101). Therefore, a hyperinsulinism phenotype may have been missed 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mice harboring human long QT syndrome-causing point mutations in Kcnq1 have also been 
described (116,117). Again, no hyperinsulinism was reported, but the mutations (T312I, 
A341V, A341E, and V207M) also differed from the mutations found in patients with long QT 
syndrome and hyperinsulinism (H363N, R366W, R401P, and Q530X) (50). 
Two homozygous Hnf1a KO mice have been published. Both models have a complex 
phenotype including impaired growth, renal and liver abnormalities, and type 2 diabetes 
(110,111). One of the models, developed by Pontoglio et al. (110), was more severely impacted 
and showed increased mortality after weaning. The other model, developed by Lee et al. (111–
113), did not show increased mortality. Hyperinsulinism was not reported for either model. 
Pontoglio et al. did not report insulin levels for their mouse, while Lee et al. stated that their 
mice were diabetic starting at 2 weeks of age and at 5 weeks plasma insulin levels were reduced 
compared to heterozygote KO mice. Overall, these mice are unlikely to reproduce the 
phenotype of Hnf1a-CHI. Instead these mice are diabetic and harbor some defects associated 
with Hnf4a-CHI, such as renal Fanconi syndrome. These findings may be explained by species 
differences. Alternatively, patients with HNF1A mutations may have some residual HNF1A 
expression and the full KO, like the full KO of KATP genes, results in a different phenotype 
characterized primarily by diabetes instead of CHI.  
Lastly, many studies aimed to target expression of CHI-associated genes specifically in the 
pancreas or β-cells. For this endeavor Pdx-cre or Rip-cre transgenic mice have been used, 
respectively (118,119). However, we now know that these models introduced changes to the 
β-cell that could influence results significantly. These transgenic mice express Cre-
recombinase under the control of the Pdx or rat insulin promoter (Rip). The constructs used to 
generate these animals included the human growth hormone (hGH) minigene to enhance the 
expression of Cre-recombinase. It was assumed that the hGH would not be expressed. 
However, in 2014 Brouwers et al. not only reported evidence for hGH expression in β-cells of 
these transgenic mice, but also that the expression of hGH altered β-cell function (120). This 
included pregnancy-like changes to β-cell mass and impaired GSIS. Interestingly, Rip-cre was 
used to generate β-cell specific Hnf4a KO mice by two separate groups (66,67). These mice 
were meant to serve as a model for MODY1, a condition that often presents with CHI in youth 
and transitions to a diabetic phenotype later in life (68). Even though both groups succeeded in 
generating the KO, the phenotypes of their mice were strikingly different. Gupta et al. reported 
a CHI phenotype for their mouse line (66), while the mouse generated by Miura et al. showed 
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impaired GSIS (67). This disparity may be explained by different genetic background of the 
two mouse lines (CD1 vs. mixed 129 Svj and C57BL/6), which could affect the phenotype 
directly or via different susceptibility for hGH expression. The latter may explain the reduced 
GSIS observed by Miura et al. 
Fortunately, newer models for selective targeting of β-cells exist that do not include the hGH 
transgene. One such model is the Ins1-cre mouse model that uses the endogenous Ins1 promoter 
for expression of Cre-recombinase (121). While this model reduces expression of the Ins1 gene, 
insulin protein levels, insulin secretion and overall glucose homeostasis were not affected 
(121). This model therefore offers a more reliable approach for the study of β-cell function 
when beta-cell-specific KO of the gene in question is needed. 
Overall, more than twenty models for eleven types of CHI have been developed and described. 
While some have been more successful in replicating the human condition, others have resulted 
in unexpected challenges. Ultimately, these models have substantially increased our 
understanding of the regulation of insulin secretion and the development and progression of 
CHI.  
1.4. Short-Chain 3-Hydroxyacyl-CoA Dehydrogenase (SCHAD) 
1.4.1. SCHAD gene and protein 
Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) is encoded by the hydroxyacyl-
CoA dehydrogenase (HADH) gene located on chromosome 4q22-26. This gene contains nine 
exons and several predicted transcripts that are produced by alternative splicing, most of which 
have not been characterized. The best characterized transcript (NM_005327.7) does not include 
exon 7 and thus expresses 8 of the 9 exons (Figure 6A). The transcript has a length of 1803 
base pairs. Translation produces a protein of 314 amino acids (aa) with a predicted molecular 
mass of ~34 kDa (Figure 6B).  
The 314 aa monomer comprises three domains (Figure 6B,C). The N-terminus contains a 
mitochondrial import signal (MIS) of 12 amino acids length that is cleaved upon entry into the 
mitochondrion resulting in the mature protein product of ~34 kDa molecular mass. The protein 
contains an N-terminal NAD+-binding domain spanning amino acids 12 – 201 connected via a 
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short and flexible linker region to a highly conserved C-terminal dimerization domain formed 










SCHAD forms homodimers through hydrophobic interactions of α-helices within the C-
terminal dimerization domains of the interacting monomers (Figure 6D). Formation of the 
homodimer is crucial for protein stability (123). The enzyme catalyzes the penultimate step of 
the fatty acid β-oxidation pathway which encompasses the conversion of 3-hydroxyacyl-CoA 
to 3-ketoacyl-CoA using NAD+ as cofactor. The N-terminal NAD+-binding domain is 
responsible for these catalytic functions. It is structurally composed of a β-α-β fold and contains 
an active site with a highly conserved His-Glu pair which functions as the catalytic domain and 
is responsible for cofactor (NAD+) and substrate binding. Upon binding of NAD+, affinity of 
SCHAD to its substrate increases. Binding of substrate to the active site then leads to 
deprotonation of the substrate by the histidine residue which acquires a positive charge that is 
subsequently neutralized by the adjacent glutamate residue (124). 
Figure 6. SCHAD gene and protein structure. A Schematic representation of the coding exons of the HADH 
gene. Exons expressed in the transcript NM_005327.7 are indicated in yellow. Exon 7, which is not included in 
this transcript is indicated in purple. B Schematic representation of the SCHAD protein. The SCHAD monomer 
has a total length of 314 aa. The N-terminal contains a mitochondrial import signal (MIS, green), followed by an 
NAD+- binding domain (red) and a C-terminal dimerization domain (blue). C 3-dimensional model of SCHAD 
monomer. The MIS is indicated in green, NAD+-binding domain in red and dimerization domain in blue color. 
The short linker region connecting NAD+-binding with dimerization domain is indicated in grey. D 3D model of 
SCHAD homodimer. Individual monomers are indicated in black and grey color. 3-dimensional models were 





1.4.2. The role of SCHAD in fatty acid β-oxidation 
Fatty acid β-oxidation is the part of fatty acid oxidation (FAO) that takes place in the 
mitochondria. It is the major catabolic pathway of fatty acids and the main source of energy 
for some organs (kidney, heart, skeletal muscle) as well as an important source of energy in 
low glucose conditions throughout the body (125).  
Long-chain fatty acids are imported into the mitochondria through the carnitine shuttle in the 
form of fatty acid acyl-CoA. Short- and medium-chain fatty acids enter the mitochondria 
through diffusion after which they are converted to fatty acid acyl-CoA (126). β-oxidation 
involves four enzymatic reactions that shorten fatty acid acyl-CoA by two carbon atoms to 
form acetyl-CoA which feeds into the TCA cycle for energy production or into ketogenesis for 











Figure 7. The fatty acid β-oxidation pathway. Enzymes are indicated in red and co-factors in purple. Fatty acid 
β-oxidation is a four-step process carried out by different enzymes specialized for different lengths of acyl-CoA 
degradation intermediates. SCHAD, a 3-hydroxyacyl-CoA dehydrogenase, carries out the penultimate step, i.e. 
the conversion of short- and medium-chain 3-hydroxyacyl-CoA to 3-ketoacyl-CoA. This reaction also requires 




In the first step, fatty acid acyl-CoA undergoes dehydrogenation to trans-2-enoyl-CoA by an 
acyl-CoA dehydrogenase. The acyl-CoA dehydrogenase in this reaction depends on the length 
of the fatty acid acyl-CoA molecule. Thus, the reaction is carried out by very-long chain 
(VLCAD), medium-chain (MCAD), or short-chain (SCAD) acyl-CoA dehydrogenase. Mice 
additionally rely on long-chain acyl CoA dehydrogenase (LCAD). The dehydrogenation of 
fatty acid acyl-CoA requires the reduction of FAD, which yields FADH2 and is subsequently 
used as substrate in the respiratory chain (125). 
The three last steps of β-oxidation are either carried out by mitochondrial trifunctional protein 
(MCP) located on the inner mitochondrial membrane or by separate enzymes within the 
mitochondrial matrix. MCP has affinity for long chain intermediates of fatty acid acyl-CoA 
while the other enzymes specialize on conversion of short- and medium- chain intermediates. 
Since SCHAD has affinity for short- and medium-chain intermediates, we will focus on 
degradation of these intermediates in the next paragraph.  
Following dehydrogenation of fatty acid acyl-CoA, trans-2-enoyl-CoA is hydrated to 3-
hydroxyacyl-CoA by the short-chain enoyl-COA hydratase, crotonase. 3-hydroxyacyl-CoA is 
subsequently dehydrogenated to 3-ketoacyl-CoA by SCHAD. This reaction requires the co-
factor NAD+ which is reduced to NADH and subsequently feeds into the respiratory chain. The 
last step in fatty acid β-oxidation is carried out by medium-chain β-ketoacyl-CoA thiolase, 
which cleaves 3-ketoacyl-CoA into acetyl-CoA and an acyl-CoA that has been shortened by 
two carbon atoms (N-2 acyl-COA). The shortened fatty acid acyl-CoA then re-enters in step 1 
of the β-oxidation pathway until the final cycle, where there are two acetyl-CoA produced 
(125). 
1.4.3. The discovery and phenotype of SCHAD-CHI 
SCHAD was first associated with CHI by Clayton et al in 2001 (127). The authors described a 
female patient from a non-consanguineous family who presented with diazoxide-responsive 
hypoketotic hypoglycemia. Surprisingly, the patient also had elevated plasma hydroxybutyryl-
carnitine levels that indicated a possible defect in fatty acid metabolism. Indeed, when the 
authors investigated the activity of FAO enzymes in fibroblasts of the patient and healthy 
controls, they found that activity of SCHAD was reduced to 35 – 40% of that of the control 
samples. This residual activity could be due to peroxisomal enzymes instead of reflecting 
residual SCHAD activity since further experiments showed a near lack of SCHAD protein 
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expression in fibroblasts of the patient. In line with this, enzyme activity was even further 
reduced when mitochondrial extracts were utilized for the assay. Finally, the authors identified 
a homozygous point mutation that changed a cytosine to thymine at position 773 in the HADH 
gene. This mutation results in the substitution of proline at position 258 with a leucine residue 
in the SCHAD protein transcript leading to SCHAD deficiency (127). 
The association of SCHAD deficiency with CHI was still unclear at this point but was 
confirmed by Molven et al. in 2004 (128). The authors described a consanguineous family 
(Figure 8) where the parents were double first cousins and four children had severe neonatal 
hypoglycemia as well as elevated plasma 3-hydroxybutyryl-carnitine and urinary 3-
hydroxyglutaric acid levels. The two eldest affected children died at four months of age due to 
hypoglycemia. The two younger affected children survived due to treatment involving frequent 
feeding, glucose administration, glucagon and eventually diazoxide therapy. The older of the 








Since no mutations in known CHI-associated genes had been identified in this family, Molven 
et al. carried out a whole-genome scan with microsatellite markers searching for homozygous 
chromosomal segments. They identified a candidate region on 4q and revealed a deletion of 
six base pairs at the beginning of exon 5 of the HADH gene. The deletion disrupts a splice site 
and leads to omission of exon 5 causing the loss of approximately 30 aa in the final SCHAD 
Figure 8. Pedigree of the consanguineous family with severe SCHAD-CHI described by Molven et al. Filled 
and open symbols denote subjects with CHI and healthy family members, respectively. Subjects IV 1 and 2 are 
deceased. Subject IV 5 was a miscarriage. Four generations of the family are shown to indicate the status of the 




protein product. SCHAD activity was subsequently shown to be reduced in fibroblasts from 
the two affected children compared to controls (128). 
These two reports linking SCHAD deficiency to CHI fully established HADH as a member of 
the metabolopathy subgroup of CHI genes. Today, at least 45 cases of SCHAD-CHI have been 
published (Table 3). 
Table 3. Published patients with CHI-causing mutations in HADH. Mutations that affect splice sites and 
introns are reported at DNA level. Mutations that affect exons are reported at the level of protein sequence. NA = 
no information available. Table extended from (82). All mutations are homozygous except the compound 
heterozygous cases no. 5, 20, 26, and 48. Case no. 5 presented with a Reye-like syndrome instead of CHI. 
Patient Gender Consanguinity  Ethnicity Onset Mutation Reference 
1 F No  Indian 4 moths P258L (127)  
2 M Yes  Pakistani 3 days IVS4-3DELCAGGTC (128) 
3 F Yes  Pakistani 1.5 h IVS4-3DELCAGGTC (128) 
4 M Yes  Pakistani 4 months IVS6-2A>G (129) 
5 F No  Caucasian 10 months D57G, Y226H (130) 
6 F Yes  Bangladeshi 4 months p.M188V (131) 
7 M Yes  Caucasian 2 months R236X (132) 
8 M Yes  Caucasian 8 months S196FfsX3 (133) 
9 F Yes  Caucasian 6 months S196FfsX3 (133) 
10 M NA  Caucasian 14 months S196FfsX3 (133) 
11 M No  Caucasian 7 months IVS2+1G>A (133) 
12 M Yes  Turkish 16 weeks K136E (134) 
13 M Yes  Turkish 16 weeks Q163X (134) 
14 M Yes  Turkish 2 weeks R236X (134) 
15 M Yes  Turkish 5 days R236X (134) 
16 F No  Turkish 1 week R236X (134) 
17 M Yes  Pakistani 2 days R236X (134) 
18 F No  Iranian 12 weeks R236X (134) 
19 F No  Iranian 1 day R236X (134) 
20 M No  Indian 26 weeks K95SfsX3, IVS6 + 
39C>G 
(134) 
21 M No  Indian 2 days Ex1deletion (134) 
22 M No  Indian 24 weeks Ex1deletion (134) 
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23 NA NA  NA NA G34R (135) 
24 NA NA  NA NA K95fs (135) 
25 NA NA  NA NA IVS8+39C>G (135) 
26 F NA  Chinese NA R10P, V30E (136) 
27 F No  Indian 12 weeks I184F (137) 
28 F No  Indian 16 weeks I184F (137) 
29 M Yes  Saudi 16 weeks IVS2-1G>A (138) 
30 F Yes  Saudi 12 weeks IVS2-1G>A (138) 
31 M Yes  Saudi 16 weeks IVS2-1G>A (138) 
32 F No  Turkish 4 weeks IVS2-1G>A (139) 
33 M Yes  Iranian 12 weeks IVS2-1G>A (140) 
34 F Yes  Iranian 1 year IVS2-1G>A (140) 
35 M Yes  Iranian 1 day IVS2-1G>A (140) 
36 F Yes  Iranian 4 days IVS2-1G>A (140) 
37 M Yes  Iranian 12 weeks IVS2-1G>A (140) 
38 M Yes  Iranian 6 weeks IVS2-1G>A (140) 
39 M Yes  Iranian 30 weeks IVS2-1G>A (140) 
40 F Yes  Iranian 1 day IVS2-1G>A (140) 
41 M Yes  Iranian 12 weeks IVS2-1G>A (140) 
42 M Yes  Iranian 12 weeks IVS2-1G>A (140) 
43 M Yes  Iranian 12 weeks IVS2-1G>A (140) 
44 M No  Caucasian NA G303S (141) 
45 M No  Indian 34 weeks T189fs (142) 
46 M Yes  Turkish Since birth I143N (143) 
47 F Yes  Turkish Since birth R236X (143) 




SCHAD-CHI requires deficiency of both alleles and follows autosomal recessive inheritance. 
The hallmarks of the condition have been established to include mild to severe diazoxide-
responsive hyperinsulinemic hypoglycemia, protein sensitivity (discussed in more detail in 
Chapter 1.4.4) and in most cases asymptomatic elevation of plasma 3-hydroxy-butyryl-
carnitine and urinary 3-hydroxyglutaric acid. The birth weights are generally normal, and there 
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is an absence of FAO-related features (e.g. liver defects or enlargement, cardiomyopathy, 
skeletal muscle defects) (82). 
1.4.4. Insights into the mechanism behind SCHAD-CHI 
As mentioned, SCHAD-deficient patients lack the classical phenotype of a FAO disorder, and 
neither 3-hydroxybutyryl-carnitine nor 3-hydroxyglutaric acid is capable of stimulating insulin 
secretion (145). Therefore, it was hypothesized that SCHAD may play a role in the regulation 
of insulin secretion that is separate from its role in FAO and that this function could be specific 
to the β-cell. Indeed, SCHAD expression in the pancreas is highest in β-cells (Figure 9), and 
its level in β-cells is disproportionally high compared to that of other FAO enzymes (146). 
Knockdown of SCHAD in insulinoma cells and isolated islets results in increased insulin 
secretion (145,147). Moreover, SCHAD mRNA expression in β-cells is regulated by FOXA2 
(71). As stated in Chapter 1.3.6, FOXA2 is another CHI-associated gene belonging to the 
transcriptionopathies. It is an important regulator of pancreas development and also regulates 












Figure 9. Immunohistochemistry of SCHAD and insulin expression in a human islet of Langerhans. 
Antibodies against SCHAD (green) and insulin (red) were used. Nuclei were stained with DAPI (blue). Source: 
Anders Molven and Jiang Hu, Joslin Diabetes Center. 
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Pull-down experiments using recombinant SCHAD protein as bait and human mitochondrial 
extracts derived from liver tissue as prey resulted in the discovery of a protein interaction 
between SCHAD and GDH (148). Activating mutations in the GDH-encoding gene, GLUD1, 
cause hyperinsulinism/hyperammonemia syndrome (see Chapter 1.3.5). Therefore, it was 
proposed that SCHAD may work as an inhibitor of GDH. 
This was later confirmed by Li et al, who characterized the full body SCHAD knockout mouse 
(SCHADKO) (85). The animal model mirrors the human SCHAD-deficient phenotype of 
amino acid-sensitive, hyperinsulinemic hypoglycemia as well as the characteristic elevation in 
plasma and urinary fatty acid metabolites. Increased sensitivity to amino acids seems to be a 
hallmark of SCHAD-CHI (131) and is also characteristic for CHI caused by increased GDH 
activity. Indeed, Li et al. showed in experiments conducted on isolated islets that the amino 
acids leucine, glutamine and alanine are responsible for the spike in insulin secretion in 
SCHAD-CHI. This effect was dependent on the presence of leucine and greatly amplified by 
the other two amino acids. The three amino acids are related to GDH activity. Leucine is an 
allosteric activator of GDH, whereas oxidation of glutamine by glutaminase produces 
glutamate which serves as a substrate for GDH. Alanine can be utilized as substrate for the 
TCA cycle. The authors also confirmed the protein interaction between SCHAD and GDH, and 
they further showed that ablation of SCHAD protein increased islet GDH activity (85). 
Overall, Li et al. demonstrated that the SCHADKO mouse is a good model for the study of 
SCHAD-CHI. However, how lack of GDH inhibition by SCHAD stimulates insulin secretion 
is still not fully understood. GDH catalyzes the reversible conversion of glutamate + NAD+ (or 
NADP+) to α-ketoglutarate + NH3 + NADH. Both directions of this reaction have the potential 
to stimulate insulin secretion. α-ketoglutarate is used as substrate in the TCA cycle and its 
metabolism ultimately leads to a rise in the ATP:ADP ratio, which in turn stimulates insulin 
secretion through closure of KATP channels (55). Glutamate on the other hand can be taken up 
by insulin granules which then leads to amplification of insulin secretion (56). Glutamine 
oxidation to glutamate is increased in SCHADKO islets but administration of glutamine alone 
does not result in increased insulin secretion (85). This may suggest that glutamine is converted 
to glutamate for the conversion to α-ketoglutarate by GDH, instead of being taken up by insulin 
granules. However, other studies suggest that the specific β-cell environment favors the 
opposite reaction. Glucose stimulation increases the mitochondrial NADH:NAD+ ratio which 
favors the production of glutamate over the production of α-ketoglutarate by GDH (149). 
38 
 
Ultimately, either way could lead to increased insulin secretion, and it is possible that both 










The above evidence confirms the hypothesis that SCHAD serves a second function outside of 
FAO, but the question remains whether this function is specific for the β-cell. Both SCHAD 
and GDH are ubiquitously expressed and some cases of SCHAD-CHI also report mild 
hyperammonemia, which poses the question whether liver or kidney defects may be involved 
in the pathophysiology (133). However, downregulation of SCHAD expression in rat 
insulinoma cells stimulates insulin secretion (145–147) and an islet transplantation study 
performed by Molven et al. suggests that the hypoglycemic phenotype of SCHAD deficiency 
is islet-autonomous (150). Molven et al. transplanted isolated islets from SCHADKO mice and 
controls under the kidney capsule of streptozotocin-diabetic mice. SCHADKO islets lowered 
the plasma glucose of recipient mice more potently than control islets. This suggests that 
SCHAD deficiency in the islet may be sufficient to cause hypoglycemia, but contribution of 
Figure 10. Proposed mechanism for regulation of GDH activity by SCHAD. GDH catalyzes the reversible 
conversion of glutamate to α-ketoglutarate and ammonia using NAD+ or NADP+ as cofactors. Its activity depends 
on stimulation by activators and inhibitors. In this proposed model, SCHAD is an inhibitor of GDH activity. 
SCHAD deficiency removes an inhibitory signal and increases GDH activity which leads to increased production 
of glutamate or α-ketoglutarate depending on the mitochondrial NADH:NAD+ ratio. This would then stimulate 
insulin secretion by increasing the β-cell ATP:ADP ratio through metabolism of α-ketoglutarate or by amplifying  




different islet cell types and the influence of other tissues could not be studied by the 
transplantation approach. 
Besides the interaction with GDH, one study indicated that SCHAD may interact with several 
other proteins, possibly within tissue-specific metabolic super-complexes (151). Pull-down and 
yeast-2 hybrid studies showed that the enzyme interacts with other mitochondrial and possibly 
cytosolic enzymes involved in metabolism of carbohydrates, glutamate, and lipids, urea cycle 
and others. Thus, even though the evidence strongly suggests a link between SCHAD and GDH 
in the pathophysiology of CHI, other interactions and pathways may be involved (151). 
Another limitation is that no structure of the postulated SCHAD-GDH complex has been 
presented. 
In summary, the FAO enzyme SCHAD is fully implicated as member of the metabolopathy 
subgroup of CHI. So far, the data suggests that SCHAD serves two distinct functions, one in 
FAO and the other in β-cell insulin secretion, and that the latter is dependent on an interaction 
with GDH. Still, many questions concerning the mechanism behind SCHAD-CHI and the role 






2. Aims of the thesis 
Almost two decades ago, the fatty acid-degrading enzyme SCHAD was identified as a regulator 
of insulin secretion because mutations in the HADH gene were shown to cause CHI. The overall 
aim of the present study was to obtain a deeper understanding of how the SCHAD protein is 
implicated in regulation of insulin secretion. 
  
The specific aims of this thesis were as follows: 
1. To establish the necessary methodology and to perform a functional evaluation of 
human HADH missense variants 
2. To investigate the tissue specificity and phenotype of SCHAD deficiency in a 
conditional SCHAD KO mouse model 






3. Summary of results 
Paper I 
Functional evaluation of sixteen SCHAD missense variants: Only amino acid substitutions 
causing congenital hyperinsulinism of infancy lead to loss-of-function phenotypes in vitro. 
Here we analyzed the stability, subcellular localization, enzymatic activity and GDH 
interaction of nine population variants of unknown significance, six previously published 
pathogenic variants and an unpublished pathogenic variant of the HADH gene. To this end, we 
developed tools for prokaryotic and eukaryotic expression and production of recombinant 
protein as well as a HEK293 SCHAD KO cell line for functional testing of variants in the 
absence of endogenous protein. 
All variants localized to the mitochondria when expressed in HEK293 SCHAD KO cells. 
Seven of the nine population variants behaved in a similar manner to wildtype (WT) SCHAD 
regarding all tested properties. The exceptions were a higher molecular weight as assessed by 
western blot for the variant p.Phe92Cys and somewhat increased enzyme activity of 
p.Met188Val. 
All CHI-causing variants differed from WT SCHAD in one or more respects. The variants 
p.Gly34Arg, p.Ile184Phe, p.Pro258Leu and p.Gly303Ser were expressed at significantly lower 
levels in HEK293 and SCHAD KO HEK293 cells. This is most likely due to abnormal folding 
followed by rapid degradation due to protein quality control since these variants could be 
expressed in a cell-free expression system devoid of functional quality control systems. 
Moreover, MG132-mediated blockage of the ubiquitin-proteasome system partially rescued 
protein expression of these variants in the HEK239 SCHAD KO cell line. 
Regarding enzyme activity, SCHAD WT displayed a Vmax of 181 ± 3 μmol/min/mg. The three 
pathogenic variants p.His170Arg, p.Pro258Leu and p.Gly303Ser, had almost no enzyme 
activity (< 10 μmol/min/mg). The variants p.Lys136Glu and p.Met188Val had significantly 
reduced enzyme activity (127 ± 8 μmol/min/mg and 132 ± 29 μmol/min/mg, respectively).  
Lastly, Co-IP experiments showed that three of the pathogenic variants with normal protein 
expression but reduced enzyme activity (p.Lys136Glu, p.His170Arg, and p.Met188Val) still 
interacted with GDH, albeit to a lower degree than WT SCHAD. 
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Overall, we showed that the tested population variants of unknown significance did not impair 
SCHAD protein function, while pathogenic variants affect protein stability, enzyme activity 
and GDH interaction to varying degrees. 
 
Paper II 
Amino acid-sensitive hypoglycemia caused by a specific deficiency of the metabolic enzyme 
SCHAD within pancreatic β-cells. 
The focus of Paper II was to investigate whether SCHAD-CHI has a phenotype that can be 
attributed to specific loss-of-function in the pancreatic β-cells. Selective removal of SCHAD 
expression from specified mouse tissues was achieved by using ES cells and the Cre-Lox 
recombination system to generate  Hadhlox/lox mice that harbored LoxP sites flanking exon 3 of 
the Hadh gene. These mice were then bred with Ins1-cre or Alb-cre mice to disrupt SCHAD 
expression in β-cells or hepatocytes, respectively. The KO was confirmed using PCR, western 
blot, and immunohistochemistry. Immunohistochemistry also demonstrated high expression of 
SCHAD in the δ-cells of the islets and an apparent absence of expression in the α-cells. 
Male and female mice were analyzed for bodyweight development and glucose homeostasis. 
Hepatocyte SCHAD KO (L-SKO) mice had no evident phenotype and were not further 
analyzed. β-cell SCHAD KO (β-SKO) mice, on the other hand, had reduced blood glucose 
levels in the random fed, 16-h fasted and refed state, and the rise in blood glucose 4 h after 
refeeding was blunted. This happened despite normal food intake during refeeding in male and 
increased food intake in female β-SKO mice. Insulin and C-peptide levels in all three 
conditions did not indicate hyperinsulinism. Male, but not female 10-week-old β-SKO mice, 
had significantly impaired glucose tolerance, but this difference disappeared when re-tested at 
30 weeks of age. 
Feeding male β-SKO mice a diet enriched in the amino acids alanine, glutamine, and leucine 
exacerbated the hypoglycemic phenotype and slightly impaired glucose tolerance. Again, 
insulin levels did not indicate hyperinsulinism. However, isolated islets derived from male β-
SKO mice displayed a marked increase in insulin secretion when stimulated with the above-
mentioned amino acids in the presence of 3.3 mM, but not 16.7 mM glucose. These amino 
acids had no additional effect in stimulating insulin secretion from control islets at either 
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glucose concentration. Female β-SKO islets displayed a similar increase in insulin secretion 
when stimulated with amino acid mixture at 3.3 mM glucose. In contrast to male β-SKO islets, 
incubation with 16.7 mM glucose elicited a reduced insulin secretion response from female 
islets that was rescued by addition of amino acid mixture. 
Analyzing the transcriptome of islets from 10-week-old male β-SKO mice revealed a global 
change in expression of genes involved in metabolism. Oxidative phosphorylation, amino acid, 
and protein metabolism were up-regulated, while lipid metabolism was down-regulated. 
Interestingly, the insulin secretion pathway was amongst the down-regulated pathways.  
Furthermore, RNAseq showed evidence for β-dedifferentiation as dedifferentiation markers, 
Aldh1a3, Aass, and others were amongst the top up-regulated genes accompanied by a decrease 
in expression of genes involved in β-cell maturation, survival, and cell adhesion. Lastly, gene 
expression of proteins involved in calcium signaling and transport suggested an increase in 
calcium binding and uptake. 
Overall, the data of Paper II demonstrated that ablation of SCHAD expression in the β-cells is 
sufficient to elicit an amino acid-sensitive, hypoglycemic phenotype akin to hypoglycemia seen 
in global SCHADKO mice and in SCHAD-deficient patients. KO of SCHAD in hepatocytes 




Searching for novel interaction partners of short-chain 3-hydroxyacyl-CoA dehydrogenase: A 
role for keratin 8? 
SCHAD has been shown to interact with a variety of proteins, and it has been speculated that 
it is part of tissue-specific metabolic super-complexes of proteins. Specific interactions within 
the islets of Langerhans have not been addressed so far. Given the high β-cell expression levels 
and SCHAD’s role in insulin regulation, we in Paper III aimed to identify novel SCHAD 
protein interactions that might be particularly relevant for its β-cell function. We therefore 
performed a yeast two-hybrid (Y2H) screen using a cDNA library from human islets.  
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By employing a bait consisting of SCHAD without its dimerization domain, we identified two 
proteins,  keratin 8 (K8) and cytospin-A (SPECC1L), with very high confidence. K8 was the 
by far dominating hit. An interaction of SCHAD with K8 could be confirmed using co-
immunoprecipitation approaches and was also supported by mass spectrometric analysis of co-
IP samples. 
SCHAD and K8 are confined to different subcellular compartments. SCHAD is transported to 
the mitochondria, while K8 is expressed in the cytosol. However, using a cytosolically 
expressed SCHAD variant (Δ1-12 SCHAD) as bait in SCHADKO HEK293 cells did not 
increase the amount of K8 in the co-IP fraction. In fact, we observed less interaction of K8 
with Δ1-12 SCHAD, indicating that the interaction may be confined to the mitochondrial 
matrix. 
K8 is a main keratin of the islet of Langerhans and with a potential role in the regulation of 
insulin secretion. We confirmed its presence in the endocrine pancreas by using 
immunohistochemistry on human and mouse tissue and by openly accessible single cell 
RNAseq data from the Tabula Muris database. Lastly, we performed a pilot study of SCHAD 
and K8 expression in their respective knockout mouse models. Absence of SCHAD expression 
did not affect K8 expression levels in whole pancreas but seemed to result in slight upregulation 
of K8 in islet preparations. Ablation of K8 expression alone had no overt effect on SCHAD 
expression in whole mouse pancreas and islets. However, when animals were fed a ketogenic 
diet, we observed significant upregulation of SCHAD in whole pancreas and this increase was 
blunted in animals lacking K8 expression.  
In conclusion, Paper III identified a possible physical interaction between SCHAD and K8. 
Whether this interaction occurs within the pancreatic β-cell and, if so, its biological relevance 




4. General discussion 
4.1. Interpretation of HADH variants identified in a clinical setting 
Whole-exome and whole-genome sequencing are powerful tools for the identification of 
underlying germline mutations in patients and families. This also holds true for rare, heritable 
genetic conditions of glucose homeostasis such as MODY and CHI. Analyzing the plethora of 
raw genetic information, however, poses a significant challenge. “Wildtype” humans do not 
exist, and every person harbors an array of rare genetic variants of unknown significance, in 
particular missense mutations, that will be picked up in the genetic screening. Missense 
mutations may or may not alter the function of the protein and, in the latter case, may or may 
not be pathogenic. Predicting functional effects of these mutations using bioinformatics tools 
is still notoriously unreliable. Thus, physicians and molecular biologists will in many cases be 
left with the conclusion that the variant is a VUS, i.e. a variant of unknown significance. 
One example is a diabetes family recruited by the Norwegian MODY Registry and screened 
for pathogenic mutation at the Bergen Diabetes Research Center as part of the clinical workup 
some years ago (Figure 11). This multigenerational family includes several family members 
with diabetic phenotypes of varying severity. Whole-exome sequencing was performed on the 
seven available DNA samples from this family. Three family members were identified to be 
heterozygous for the known, pathogenic GCK mutation p.Ser453Leu. Thus, these patients were 
diagnosed with GCK-MODY (MODY2). The other four sequenced family members, who were 
previously diagnosed with either type I-like diabetes or impaired fasting glucose, did not harbor 
the GCK mutant but were found to be heterozygous for the rare HADH variant p.Pro215Thr. 
This HADH variant was absent in the family members with GCK mutations. 
At the time of screening, the effect of p.Pro215Thr on SCHAD protein function was unknown. 
Thus, it was unclear whether the observation of the variant in the diabetes family depicted 
below was a spurious finding or if it represented a novel implication for SCHAD in β-cell 
function. Notably, HADH has not been associated with diabetes. In fact, there is an indication 
from the literature that rare variants of HADH might have a protective effect with regard to this 
disease (152). Still, it was not unreasonable to consider that some amino acid substitutions 
could alter SCHAD protein function in ways that could impair insulin secretion and cause a 
diabetic phenotype. This would be analogous to the situation for other central β-cell genes such 
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as GCK, HNF1A, HNF4A and ABCC8 that can cause MODY or CHI depending on the type of 











In Paper I, we analyzed the protein products of 16 HADH missense variants for expression and 
function. This study also included p.Pro215Thr, which was examined for protein stability, 
intracellular localization and enzyme activity. Only the latter differed from that of the wildtype 
protein: the activity of p.Pro215Thr was slightly but significantly elevated. The effect on 
insulin secretion by increased β-cell SCHAD activity has so far not been investigated. 
However, since the p.Pro215Thr variant was present in the heterozygous state in the four 
affected family members, it was deemed unlikely that the very modest increase in enzyme 
activity could be linked to a diabetic phenotype. Based on the findings of Paper 1 and a carrier 
frequency of 0.00184 in the gnomAD database, we therefore concluded that the identification 
of the p.Pro215Thr variant was an unrelated, spurious finding and that the variant is likely 
benign. Thus, an underlying, genetic cause for the phenotype of the non-GCK mutation carriers 
of the family in Figure 11 has not yet been revealed.  
Figure 11. Multigenerational family with diabetes and impaired fasting blood glucose. Whole-exome 
sequencing was performed for the seven members for whom DNA was available (black dots). The color codes 
show their diagnoses before sequencing. Three members were found to carry the pathogenic GCK mutation 
p.Ser453Leu in the heterozygous state, leading to the conclusion that they have MODY2. In the four other 
sequenced members, GCK was normal. However, they were all heterozygous carriers of the rare HADH variant 
p.Pro215Thr. HADH was normal in the GCK mutation carriers.  
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Still, in future studies, overexpression of p.Pro215Thr in the presence or absence of 
endogenous wildtype SCHAD in β-cell models such as the lines INS-1E or EndoC-βH1 should 
be done. This might reveal if this variant has an insulin-reducing effect not seen for the CHI-
causing variants of the HADH gene. 
4.2. Heterogeneous expression of SCHAD in islet cell subtypes.  
In Paper II, we created conditional SCHAD KO mice and deleted SCHAD expression 
specifically from β-cells using Ins1-cre mice. As part of the validation of the KO, we performed 
immunohistochemistry on pancreas sections of β-SKO mice and controls. The absence of 
SCHAD immunostaining in β-cells confirmed the successful KO, and also highlighted the high 
expression level of SCHAD in δ-cells and the very low or virtually absent expression of 
SCHAD in α-cells. This heterogeneous expression pattern in islets was previously reported by 
Lawlor et al. (154) and  Martens et al. (155), and was further confirmed in Paper III by openly 
accessible single cell RNA sequencing data from Tabula Muris (156). 
The different levels of SCHAD expression may reflect a closer developmental relationship 
between β- and δ- cells as opposed to β- and α- cells. As stated in Chapter 1.1.1, the endocrine 
cells of the pancreas share a common progenitor in neurogenin 3-positive (Ngn+) cells. Ngn+ 
cells start to emerge at embryonic day 8.5 (E8.5) in mice. Here, Ngn3+ cells first give rise to 
α-cells at E9.5, followed by β-cells at E10.5, δ-cells at E14, and PP-cells at E18.5. In humans, 
endocrine cells develop between weeks 7 and 23 of gestation. Again, α-cells develop first 
during week 7, followed by the other endocrine cell types between week 8 and 10 of gestation 
(3). 
The factors that determine cell fate during development are not fully understood and have so 
far mostly been studied in the mouse. Part of the process is the timed expression of a complex 
network of transcription factors (Figure 12). Ngn3 regulates expression of many downstream 
transcription factors important for endocrine islet cell development, including neuronal 
differentiation 1 (NeuroD1), paired-box 6 (Pax6), ISL LIM homeobox 1 (Isl1), MAF BZIP 
transcription factor B (Mafb), NK2 homeobox 2 (Nkx2.2), and regulatory factor X6 (Rfx6). At 
E9.5, endocrine progenitors begin to express paired-box 4 (Pax4) and aristaless-related 
homeobox gene (Arx). These transcription factors are mutual inhibitors and are involved in the 
separation of the lineage into β/δ and α/PP cells. The former then gives rise to β-cells 
characterized by expression of insulin (Ins), MAF BZIP transcription factor A (Mafa), Pax4/6, 
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pancreatic and duodenal homeobox 1 (Pdx1), NK6 hHomeobox 1 (Nkx6.1), and Nkx2.2., as 
well as δ-cells characterized by expression of Sst. From the combined α/PP cells, α-cells arise, 
expressing glucagon (Gcg), Arx, Mafb, Rfx6, Nkx2.2, NeuroD1, and Pax6. PP-cells are 
characterized by expression of Ppy (157). Thus, α-cells develop earlier than β- and δ-cells, and 
β- and δ-cells share a common, immediate progenitor.  
 
Islet SCHAD expression rises during embryogenesis and peaks postnatally as islets mature 
(158). RNA sequencing data from Tabula Muris confirmed the high expression of SCHAD in 
β- and δ-cells and showed high expression of SCHAD in PP cells. SCHAD is also highly 
expressed in pancreatic ductal cells which diverge from common pancreatic progenitor cells 
before the emergence of the Ngn3+ endocrine progenitor cell. It is thus possible that SCHAD 
expression is specifically silenced in α-cells after α/PP cell development. The developmental 
stage when SCHAD expression is suppressed in α-cells and identity of the transcription factors 
Figure 12. Transcription factors involved in differentiation of Ngn+ cells into endocrine islet cell types. 
Hormones and transcription factors are indicated in bold and roman font, respectively. α-, β-, δ-, and PP-cells 
share a common neurogenin 3 (Ngn3)-expressing endocrine progenitor cell. Expression of the mutually inhibitory 
paired-box 4 (Pax4) or aristaless-related homeobox gene (Arx) drives the cells towards the β/δ or α/PP lineage. 
The former gives rise to mature insulin (Ins)-producing β-cells and somatostatin (Sst)-producing δ-cells while the 
latter diverges into glucagon (Gcg)-producing α-cells and pancreatic polypeptide (Ppy)-producing PP-cells. 




that are involved in the process are not yet known. Obviously, high expression of SCHAD is a 
characteristic of mature β-cells. Identification of the developmental processes that regulate 
expression of HADH would be beneficial for understanding islet endocrine cell differentiation 
that could have implications for the development of β-cell-like cells from induced pluripotent 
stem cells (iPSC).  
4.3. A role for SCHAD in amino acid sensing? 
As discussed previously, β- and δ-cells express high levels of SCHAD while expression in α-
cells is strikingly low. Besides reflecting similarities and differences in differentiation, the 
heterogeneous expression pattern suggests that it is of relevance for proper functioning of the 
different islet cell types. In particular, the striking differences between α- and β-cells is worth 
discussing.  
In Chapter 1, we reviewed insulin secretion from β-cells and briefly discussed glucagon 
secretion from α-cells. Both cell types are intricately regulated by nutrients, paracrine, 
autocrine, and nervous system factors. Besides glucose, amino acids are potent stimuli or 
enhancers of insulin and glucagon secretion. Many amino acids enhance glucose-stimulated 
insulin secretion in mature islets, but only leucine is capable of eliciting an insulin secretion 
response by itself (4).  
During embryogenesis, however, insulin secretion is differently regulated. Here, insulin 
secretion does not follow the rise and fall of blood glucose levels. Instead, insulin is 
continuously secreted and regulated by a steady supply of nutrients by the mother (159). A 
recent study showed that in utero, amino acids may play a larger role in stimulating insulin 
release than glucose (160). Glucose responsiveness, where insulin secretion in low-glucose 
conditions is suppressed and stimulated as glucose levels increase, develops shortly after birth 
when the newborn adapts from a constant supply of nutrients to an environment where nutrient 
levels change response to feeding and fasting. During this transition, β-cells mature to become 
primarily responsive to glucose whereas amino acids take on a secondary role (160).  
We speculate that SCHAD is part of the machinery involved in regulating the switch from pre- 
and postnatal β-cell metabolism due to its role in β-cell amino acid metabolism. SCHAD 
expression rises during embryogenesis but only reaches full expression levels in mature islets 
(158). The enzyme most notably regulates amino acid metabolism through inhibition of GDH 
50 
 
(85). Neither CHI-causing GDH nor SCHAD mutations are associated with an increased risk 
for macrosomia (82,161). Thus, it is unlikely that these mutations cause fetal hyperinsulinism 
and that increased insulin secretion may develop in the postnatal period as β-cells mature.  
However, our RNA sequencing data in Paper II suggests a general increase in amino acid and 
protein metabolism and a loss of β-cell identity in islets that lack β-cell SCHAD expression. 
Perhaps, SCHAD controls amino acid metabolism beyond the scope of GDH inhibition. It is 
proposed to associate with tissue-specific metabolic super-complexes (151), yet little is known 
about β-cell-specific interactive networks of SCHAD. Thus, it is possible that SCHAD 
regulates function and/or activity of other metabolic enzymes involved with amino acid 
metabolism. 
Lack of SCHAD expression could thus impair β-cell maturation and allow for the resurgence 
or continuance of some features of amino acid-stimulated insulin secretion seen in utero. In 
SCHAD-CHI patients, this may manifest as the increase in sensitivity to protein- and especially 
leucin-stimulated insulin secretion (162). It will be intriguing to reveal the full extent of 
SCHAD’s role in amino acid sensing and β-cell maturation.  
α-cells secrete glucagon, which in concert with insulin, tightly regulates glucose levels. 
However, α-cell function is also intimately intertwined with systemic amino acid metabolism. 
For example, α-cells secrete glucagon in response to amino acids such as arginine, alanine, and 
glutamine while being inhibited by isoleucine. Leucine stimulates glucagon secretion at 
physiologic levels; however, it becomes a negative regulator when leucine levels rise (163). 
Glucagon in turn regulates hepatic amino acid metabolism and disruption of hepatic glucagon 
signaling has widespread effects on α-cell function (164). 
Studies in KO mice and mice with acute interruption of glucagon signaling showed that 
absence of glucagon signaling in the liver results in hyperaminoacidemia due to altered liver 
amino acid catabolism (165,166). The elevated serum amino acids, primarily glutamine, 
stimulated α-cell hyperplasia and hyperglucagonemia. In contrast, β- and δ-cell numbers did 
not change in response to increased amino acid levels (164). Interestingly, α-cell hyperplasia 
is partially driven by upregulation of the sodium-coupled neutral amino acid transporter 
Slc38a5. Expression of this transporter is usually restricted to embryogenesis. Slc38a5 may 
thus be part of the machinery that drives α-cell differentiation and proliferation during 
development and may reflect the difference in nutrient supply during embryogenesis  
(167,168). Overall, these experiments identified a role for α-cells in amino acid sensing and a 
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specialized liver-α-cell axis that controls systemic amino acid metabolism and α-cell 
proliferation regulated by glutamine. Disruption of α-cell amino acid sensing could therefore 
have detrimental effects on α-cell function.  
Since α-cell hyperplasia is primarily driven by glutamine, GDH activity may be part of the 
mechanism connecting amino acid sensing to α-cell proliferation. As stated in Chapter 1.4.4 
glutamine serves as substrate for GDH after conversion to glutamate. Furthermore, GDH has 
previously been proposed to function as an amino acid sensor in autophagy due to its activity 
being partially coupled to leucine availability (169). α-cells express exceptionally low levels 
of SCHAD and thus lack this level of GDH inhibition. Perhaps, α-cells rely on GDH-mediated 
amino acid sensing to a higher degree than β- and δ-cells due to glutamine-mediated regulation 
of α-cell proliferation. SCHAD expression and SCHAD-mediated inhibition of GDH could 
therefore be detrimental for α-cell function and the liver-α-cell axis. Overexpression studies of 
SCHAD in α-cells could potentially elucidate the role of SCHAD in amino acid sensing and 
should be pursued in future experiments. 
4.4. Novel SCHAD interaction partners. A role for keratin 8? 
SCHAD protein interactions have been investigated in a variety of tissues such as liver, heart, 
skeletal muscle, brain, and kidney (151). Associations were then found with tissue-specific 
proteins and even with cytosolic proteins. The idea of Paper III of this thesis was to search for 
novel SCHAD protein interactions that might be specific for the islets of Langerhans. We 
performed a Y2H screening and identified K8 as a possible interaction partner of SCHAD. 
That there was no hit for GDH in this screening, might at first glance appear surprising since a 
previous study identified GDH in a similar experiment (151). However, the authors used a 
human placental cDNA library and a shorter SCHAD peptide spanning residues 75 – 119 as 
prey and bait, respectively. Thus, the discrepancy in Y2H results may indicate different 
availability of prey proteins depending on the studied tissue. Our results do not exclude that 
SCHAD interacts with GDH in the β-cell. Instead they may indicate that the interaction with 
K8 is sufficiently strong to mask interactions with GDH in our experimental set-up. This would 
be analogous to what happened in the first Y2H screen performed in Paper 1, where SCHAD 
dimerization dominated all other interactions in the β-cell cDNA library. 
In Paper III, we therefore decided to focus our studies regarding possible interactions of 
SCHAD on keratin K8 due to the overwhelming dominance of this interaction in the Y2H 
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screen. Moreover, a previous report on K8KO mice had demonstrated a role for K8 in β-cell 
function and glycemic control (170). Indeed, the K8KO mouse is, similar to the SCHADKO 
model, hypoglycemic. It has been hypothesized that the reason for this phenotype in the mice 
lacking K8 may be an increase in insulin action, glucose uptake, and hepatocyte glycogen 
storage (170,171) while hypoglycemia in SCHAD-deficient mice may be the consequence of 
increased β-cell sensitivity to amino acid-stimulated insulin secretion (85,150). However, 
K8KO mice show evidence for defects related to the insulin secretion pathway. β-cell 
ultrastructure, specifically insulin vesicle morphology and mitochondrial mobility, have been 
found abnormal, and GLUT2 is retained in the cytoplasm instead of in the β-cell membrane 
(170,172). Consequently, K8KO mice have impaired GSIS and are less sensitive to 
streptozotocin-induced β-cell damage. Amino acid-stimulated insulin secretion has not yet 
been studied in K8KO mice. Overall, both SCHAD and K8 are implicated in β-cell function 
and absence of either protein directly affects the insulin secretion pathway. Thus, the possibility 
exists that lack of an interaction between SCHAD and K8 is part of the defects seen in each 





5. Concluding remarks 
CHI is a rare, inherited condition characterized by inappropriately elevated insulin secretion, 
hypoglycemia, and associated health complications. It is caused by mutations in genes involved 
in the regulation of insulin secretion from pancreatic β-cells. Thus far, around fifteen genes 
have been identified to cause CHI through changes at the level of small molecule transport, 
nutrient metabolism and gene expression. Studying CHI-associated genes therefore offers a 
unique opportunity to investigate β-cell biology and has the potential for identification of 
therapeutic targets not only for CHI, but also for diabetes mellitus. 
In this thesis, I have examined the function and possible protein interactions of one such gene, 
HADH, which encodes the fatty acid oxidation enzyme SCHAD. In Paper I, we developed 
toolkits for the study of HADH missense variants and concluded that rare variants observed in 
the general population are not functionally affected. In Paper II, we investigated the tissue 
specificity of SCHAD-CHI using conditional SCHAD KO mice, demonstrating that it is 
primarily a β-cell disease. Finally, in Paper III, we aimed to identify novel islet-specific protein 
interaction partners of SCHAD. 
Overall, the work presented in this thesis offers new insights into rare HADH variants and their 
effects on the SCHAD protein, the functional importance of SCHAD expression in β-cells, and 
– potentially – its islet-specific interactions. Our studies may hopefully aid in future research 
unravelling precisely how SCHAD is implicated in the insulin secretion pathway and which 




6. Future perspectives 
The experimental systems for SCHAD functional studies developed in Paper I included 
eukaryotic and prokaryotic expression vectors, as well as a HEK293 SCHAD KO cell line for 
eukaryotic overexpression of the variants in the absence of endogenous SCHAD protein. In the 
paper, we studied a total of 16 missense variants, and the developed toolkit will facilitate 
studies of newly discovered missense variants. 
Future experiments would also benefit from the development of a SCHAD-deficient β-cell line 
(e.g. INS-1E (173) or EndoC-βH1 (174)) and transgenic β-cell lines expressing pathogenic 
variants of SCHAD under the control of the HADH promoter. Using β-cell lines would offer 
the possibility to study the effect of overexpression of pathogenic variants and the effect of 
increased SCHAD enzyme activity of the non-pathogenic P215T variant on insulin secretion 
in the absence of endogenous wildtype SCHAD. These cells would also enable the 
identification of protein interaction partners in the β-cell using co-immunoprecipitation with 
either overexpressed wildtype SCHAD or missense mutants as bait. The latter could be 
generated by targeted mutagenesis using CRISPR technology and would allow for more 
comprehensive analysis of the effect of pathogenic missense mutations as SCHAD variants 
would be expressed at natural levels. 
Since SCHAD-CHI is widely accepted to be caused by a lack of GDH inhibition by SCHAD 
(85), understanding the interaction of SCHAD with GDH is of utmost importance. The 
determination of the structure of the two proteins in complex would represent a major leap 
forward in understanding their mechanism of interaction. SCHAD is expressed at particularly 
high levels in β-cells compared to GDH or other FAO enzymes (146). Indeed, a SCHAD:GDH 
ratio of 3:1 is required for inhibitory action by SCHAD (85). Furthermore, SCHAD-CHI 
patients are sensitive to leucine, an allosteric activator of GDH (162). Whether SCHAD blocks 
GDH directly or prevents allosteric activation by leucine remains to be investigated. Using 
GDH enzyme activity assays in combination with recombinant SCHAD protein generated in 
Paper I, this inhibitory interaction could be modulated by addition of allosteric activators (e.g. 
leucine) or inhibitors (e.g. GTP). Lastly, using pull-down experiments we showed that the 
tested pathogenic missense variants with normal protein expression level (e.g. p.Lys136Glu, 
p.His170Arg, and p.Met188Val) interacted with GDH to a lower degree than wildtype SCHAD 
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protein. Using these mutant SCHAD proteins as inhibitors in a GDH activity assay could shed 
more light on their effect compared to wildtype SCHAD. 
In Paper II, we demonstrated that SCHAD deficiency limited to the insulin producing β-cell is 
sufficient to cause a hypoglycemic phenotype in β-SKO mice and that this phenotype can be 
exacerbated by feeding of a diet enriched in leucine, alanine, and glutamine. There are a number 
of experiments that await completion. Firstly, we did not detect overt hyperinsulinism in vivo. 
However, we only measured plasma insulin and C-peptide levels at the time of hypoglycemia. 
Insulin is not a reliable biomarker of hyperinsulinism and frequently does not show up as 
elevated in blood samples from CHI patients (74). To establish a hyperinsulinemic phenotype 
in β-SKO mice we could measure additional markers such as IGFBP-1, b-hydroxybutyrate, 
and free fatty acids. Secondly, RNA sequencing performed on islet samples of β-SKO mice 
and controls showed global changes in gene expression related to metabolism and β-cell 
identity. To confirm our findings, we will perform immunohistochemistry of selected hits on 
pancreas sections of control and β-SKO mice. Thirdly, we have also performed mass 
spectrometry analysis on plasma samples from mice fed an amino acid-enriched diet. The goal 
is to investigate whether the feeding of the diet increased metabolites related to leucine, alanine, 
and glutamine metabolism in circulation. We are currently working on finalizing the data 
analysis and are designing experiments for result validation. 
Due to the development of the Hadhflox/flox mouse, we now possess a tool to study the 
importance of SCHAD in any desired cell-type, provided that appropriate Cre-models exist to 
generate the conditional KO. Thus far, we have analyzed SCHAD KO in β-cells and 
hepatocytes. Future experiments should include the KO of SCHAD in δ-cells. δ-cells are of 
interest due to their regulatory role in hormone secretion in the islet of Langerhans. As stated 
in Chapter 1.1.3, SST secretion is similarly regulated as insulin secretion (11). Indeed, δ-cells 
express high levels of SCHAD (154) and thus SCHAD may play an important role in the SST 
secretory pathway. As of today, no models that allow for conditional KO of genes specifically 
in pancreatic δ-cells have been described. Until such a model is developed, the general 
SCHADKO mouse developed by Li et al. (85) could be used to investigate δ-cell function in 
the absence of SCHAD expression.  
Finally, in Paper III, we identified an interaction of SCHAD with K8 using a human islet of 
Langerhans library in a Y2H screening experiment. Islets of Langerhans also include other 
endocrine pancreas cells and while we performed a validating Co-IP experiment in HEK293 
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cells, we have not yet studied the postulated interaction in β-cell lines. Since both proteins are 
implicated in β-cell function and glycemic control is perturbed in KO mouse models of either 
protein, future research should focus on the possible implications of this interaction in the 
insulin secretion pathway. Here, β-cell lines such as the human EndoC-βH1 cells (174) will be 
instrumental. These cells could also be used to identify the suggested mitochondrial pool of 
K8/K18 using advanced imaging techniques and to study the effect of β-cell stress (e.g. 
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Abstract
Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), encoded by the
HADH gene, is a ubiquitously expressed mitochondrial enzyme involved in
fatty acid oxidation. This protein also plays a role in insulin secretion as reces-
sive HADH mutations cause congenital hyperinsulinism of infancy (CHI) via
loss of an inhibitory interaction with glutamate dehydrogenase (GDH). Here,
we present a functional evaluation of 16 SCHAD missense variants identified
either in CHI patients or by high-throughput sequencing projects in various
populations. To avoid interactions with endogenously produced SCHAD pro-
tein, we assessed protein stability, subcellular localization, and GDH interac-
tion in a SCHAD knockout HEK293 cell line constructed by CRISPR-Cas9
methodology. We also established methods for efficient SCHAD expression
and purification in E. coli, and tested enzymatic activity of the variants. Our
analyses showed that rare variants of unknown significance identified in
populations generally had similar properties as normal SCHAD. How-
ever, the CHI-associated variants p.Gly34Arg, p.Ile184Phe, p.Pro258Leu,
and p.Gly303Ser were unstable with low protein levels detectable when
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expressed in HEK293 cells. Moreover, CHI variants p.Lys136Glu, p.His170Arg,
and p.Met188Val presented normal protein levels but displayed clearly
impaired enzymatic activity in vitro, and their interaction with GDH
appeared reduced. Our results suggest that pathogenic missense variants of
SCHAD either make the protein target of a post-translational quality control
system or can impair the function of SCHAD without influencing its steady-
state protein level. We did not find any evidence that rare SCHAD missense
variants observed only in the general population and not in CHI patients are
functionally affected.
KEYWORD S
congenital hyperinsulinism of infancy, HADH, loss-of-function mutations, SCHAD, short-chain
3-hydroxyacyl-CoA dehydrogenase, variants of unknown significance
1 | INTRODUCTION
An increasing challenge of clinical medicine is how to han-
dle the wealth of information provided by high-throughput
genetic analyses. For a given patient, techniques such as
whole-exome and whole-genome sequencing may reveal
multiple, rare genetic variants that are of unknown signifi-
cance with regard to health implications.1 Predicting the
functional effect based on bioinformatics analyses alone is
still unreliable, particularly for missense mutations; that is,
when the genetic variant results in amino acid substitu-
tions at the protein level. This problem has, for example,
been illustrated by studies of HNF1A variants implicated in
monogenic diabetes.2
A concerted effort to functionally evaluate missense
variants of the HADH gene has so far not been
performed. This gene encodes short-chain 3-hydroxyacyl-
CoA dehydrogenase (SCHAD; EC 1.1.1.35), a mitochon-
drial protein expressed in all cells. It exerts a general
metabolic function by catalyzing the third step of
β-oxidation of short- and medium-chain fatty acids.3 In
addition, SCHAD has a specific role in glucose homeosta-
sis by inhibiting insulin secretion in the pancreatic
β-cells,4-7 most likely through an inhibitory effect on the
activity of another metabolic enzyme: glutamate dehy-
drogenase (GDH).8,9 Thus, a number of recessive muta-
tions in the HADH gene have been found to cause
congenital hyperinsulinism of infancy (CHI; OMIM #
609975).10-12 CHI is a disease characterized by inappro-
priately elevated plasma concentrations of insulin,
resulting in episodes of hypoglycemia that may become
life-threatening if not treated correctly.13,14
The gnomAD data set contains 155 HADH missense
variants, of which 154 are rare with an allele
frequency < 0.01.15 Only few of the SCHAD-CHI case
reports have examined protein expression and enzymatic
activity of the mutation in question.10,16,17 In addition, a
study of the C. elegans SCHAD protein experimentally
evaluated the structural and functional impact of two
amino acid substitutions in the conserved dimerization
interface of the protein.18
Here we have initiated a systematic assessment of
SCHAD amino acid substitutions by establishing a
toolkit of prokaryotic and eukaryotic expression vectors
for producing the protein variants as well as a SCHAD
knockout cell line for functional testing. We have
tested 16 naturally occurring missense variants for sta-
bility, subcellular localization, enzymatic activity and
GDH interaction. Overall, our data showed that
SCHAD variants reported in CHI patients display vari-
ous loss-of-function phenotypes, whereas functional
defects were not seen in any rare variant of the general
population.
2 | MATERIALS AND METHODS
2.1 | Plasmids
The complete coding sequence of the human HADH gene
(transcript variant 2, NCBI reference sequence
NM_005327.4) was synthesized (DNA 2.0) flanked by
sites for the restriction enzymes EcoRI and XhoI. For
eukaryotic SCHAD expression, the synthetic gene was
transferred to expression vector pcDNA3.1/V5-His B
(Invitrogen). The insert was cloned in-frame with the C-
terminal V5/His tag using EcoRI/XhoI and the Quick
Ligation Kit (NEB).
For prokaryotic expression, the synthetic gene served
as template to amplify HADH without the mitochondrial
import signal. Overhangs with BsmI and NcoI sites were
added in the 50-end and an Acc65I site in the 30-end. PCR




Fidelity PCR polymerase (Thermo Fisher Scientific) was
used with annealing at 53.2C for 20 seconds. The PCR
product was blunt-end-cloned into the vector pJet1.2
(CloneJET PCR Cloning Kit, Thermo Fisher Scientific).
Subsequently, the HADH insert of the pJet1.2 vector was
ligated to the pETM41-His/MBP expression vector in-
frame with an N-terminal 6His/Maltose Binding Protein
(MBP) tag (Quick Ligation Kit). Restriction enzymes
Acc65I/BsmBI were used for the insert and Acc65I/NcoI
for the vector.
Sixteen missense variants chosen from the gnomAD
data set15 (transcript ENST00000309522) and from CHI
case reports were introduced in the plasmids by using the
QuickChange II XL Site Directed Mutagenesis Kit
(Agilent). This kit was also used to delete the SCHAD
mitochondrial import signal (Δ2-12 construct). Primers
used to produce each variant are listed in Table S1.
The plasmid Plu-CMV-hGDH for over-expressing
human GDH was kindly provided by Dr Charles Stanley,
Philadelphia.
For propagation, all plasmids were heat shock-
transformed into One Shot TOP10 competent E. coli.
Plasmids were prepared by the QIAfilter Plasmid Midi
Kit (QIAGEN) and controlled by linearization/agarose
gel electrophoresis and Sanger sequencing.
Empty vector (EV) pcDNA3.1/V5-His B was used as
negative control in the expression studies. Theoretical
molecular masses were estimated using the ProtParam
tool on the ExPASy server.19 All sequence analyses for
site-directed mutagenesis and for CRISPR-Cas9 genome
editing (below) were performed by the SnapGene soft-
ware (GSL Biotech).
2.2 | Antibodies
To detect SCHAD protein by western blotting, different
polyclonal antibodies were used: rabbit anti-SCHAD
(Atlas Antibodies, HPA039588; GeneTex, GTX105167)
and goat anti-SCHAD (Novus Biologicals, NB100-77343).
A custom-made monoclonal mouse anti-SCHAD anti-
body (epitope QTEDILAKSK) from Abmart was
employed in some experiments. Mouse anti-V5
(R960-25), anti-mouse HRP conjugate (626520), anti-
rabbit HRP conjugate (656120), anti-mouse Alexa Fluor
488 conjugate (A-11017), and goat anti-GLUD1/2
(PA5-19267) were from Thermo Fisher Scientific. Rabbit
anti-β-tubulin (ab6046) and anti-β-catenin (ab32572)
were from Abcam. Mouse IgG2a (X0943) was
from DAKO.
2.3 | Establishment of a HEK293 SCHAD
knockout (KO) cell line by CRISPR-Cas9
The gRNAs 50-CACCGCACGGAACGCATGAACTGCC-
30 and 50-AAACGGCAGTTCATGCGTTCCGTGC-30,
targeting the sequence 50-CCAGGCAGTTCATGCG
TTCCGTG- 30 in the proximity of the HADH start codon
were designed via the website http://crispr.mit.edu. After
phosphorylation by T4 polynucleotide kinase, the gRNAs
were kept at 95C for 5 minutes, annealed by decreasing
the temperature to 25C (rate: 5C/min), ligated into the
pSpCas9(BB)-2A-Puro (PX459 v.2) plasmid (Addgene)
using BbsI sites, and transformed into One Shot TOP10
competent E. coli. Plasmid preparations were sequenced
using the primer 50-GAGGGCCTATTTCCCATGATT-30.
Human embryonic kidney (HEK293) cells (Clontech)
were transfected for 48 hours using the calcium phos-
phate method. Cells carrying plasmid were then selected
using 3 μg/mL puromycin in the growth medium for
96 hours. Surviving cells were detached with trypsin, and
single cells were hand-picked and transferred to individ-
ual wells in a 96-well plate. HADH exon 1 was sequenced
in surviving clones using the primers 50-
TCAACGCTGGGACGTTACA-30 and 50-GTGAAAACT
CCCTGGTGTCG-30. Finally, SCHAD expression in the
generated cell lines was evaluated by western blotting.
2.4 | HEK293 cell culture, SCHAD-V5
plasmid expression, western blotting
HEK293 cells (WT and SCHAD KO) were cultured in
DMEM medium supplemented with 10% FBS (Gibco)
and PenStrep (Sigma-Aldrich), and maintained in 5%
CO2 at 37C. Unless indicated otherwise, Lipofectamine
2000 (Thermo Fisher Scientific) was used for
transfection.
Treatment with the proteasome inhibitor MG132
(Sigma-Aldrich) was done 24 hours after transfection.
The culture medium was removed, and cells were incu-
bated with 5 μM MG132 or an equivalent volume of
DMSO in fresh medium for the specified amount of time.
To produce HEK293 whole-cell lysates, cells were
incubated in RIPA buffer (Thermo Fisher Scientific) and
centrifuged at 14 000g for 15 minutes at 4C to obtain a
clear supernatant. Protein concentration was measured
using the Pierce BCA protein assay kit (Thermo Fisher
Scientific).
For western blotting, the samples were mixed with
loading buffer and reducing agent, heated at 70C for
10 minutes and subjected to SDS-PAGE before transfer to
a PVDF membrane. The proteins of interest were
detected using specific antibodies and visualized by
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enhanced chemiluminescence using Amersham ECL
Prime Western Blotting detection reagent
(GE Healthcare) and a GBOX I Chemi XR5 imager
(Syngene).
2.5 | Cell-free expression of SCHAD-V5
plasmids
Cell-free expression of SCHAD variants was achieved by
incubating the pcDNA3.1-SCHAD-V5-His plasmids in
TNT T7 Quick Coupled Transcription/Translation master
mix (Promega). Each reaction was incubated for
90 minutes at 30C, and 3 μL were analyzed by western
blotting.
2.6 | Immunostaining and microscopy
HEK293 SCHAD KO cells were grown on poly-L-
lysine coated glass coverslips. To label the mitochon-
dria, cells were incubated for 30 minutes in 200 nM
MitoTracker Red CMXRos (Invitrogen) diluted in pre-
warmed cell medium. Cells were fixed for 15 minutes
with 4% paraformaldehyde, permeabilized with 0.2%
Triton X-100 in PBS and blocked with 1% BSA,
22.5 mg/mL glycine, 0.1% Tween in PBS. To stain for
SCHAD-V5, the cells were incubated consecutively
with the anti-V5 and anti-mouse Alexa Fluor 488 con-
jugate antibodies. Each incubation was 1 hour at room
temperature, with three PBS washes of 5 minutes in
between. Coverslips were mounted in ProLong Gold
Antifade Reagent with DAPI (Cell Signaling Technol-
ogy). The confocal images were collected using a TCS
SP5 confocal microscope with a 63×/1.4NA HCX Plan-
Apochromat oil immersion objective, ~1.0 airy unit
pinhole aperture, and appropriate filter combinations
(Leica Microsystems). Images were acquired with
405 diode, argon and DPSS 561 lasers and processed
using the LAS AF software.
2.7 | MBP-SCHAD protein expression
and purification
MBP-SCHAD plasmids were transformed into BL-21
(DE3) E. coli cells (NEB) by the heat shock method. A
single colony was inoculated and grown in LB medium
with 1% glucose and 50 μg/mL kanamycin at 37C. Pro-
tein expression was induced at OD600 = 0.6 by adding
0.1 mM IPTG. Bacteria were harvested after overnight
incubation at 22C and sonicated in a pH 7.8 buffer
(50 mM NaH2PO4, 500 mM NaCl, 10 mM imidazole,
0.1 mM DTT, 10% glycerol) complemented with
EDTA-free protease inhibitors (Roche). Recombinant
SCHAD protein was purified by immobilized metal
affinity chromatography (IMAC) on a HisTrap HP
5-mL column (GE Healthcare) followed by size exclu-
sion chromatography (SEC) on a Superdex
200 16/60120-mL column (GE Healthcare). Buffers
(pH 7.8) were as follows: IMAC wash buffer (50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, 0.1 mM
DTT, 10% glycerol), IMAC elution buffer (= wash
buffer with 250 mM imidazole), SEC buffer (50 mM
NaH2PO4, 150 mM NaCl, 0.1 mM DTT, 10% glycerol).
Fractions were analyzed by SDS-PAGE and
Coomassie staining (SimplyBlue SafeStain, Invi-
trogen) and protein concentration was determined by
A280 measurements.
2.8 | Multiangle light scattering
measurements
The molecular mass of MBP-SCHAD was calculated by
SEC-MALS using a Superdex 200 HR 10/30 column
coupled to a light-scattering device. Bovine serum albu-
min (BSA) was used as standard.
2.9 | SCHAD enzymatic assay
The enzymatic reaction was started by adding 0.07 μg of
purified MBP-SCHAD protein to 1.0 mL 100 mM potas-
sium phosphate buffer (pH 7.0) containing 0.1 mM DTT,
0.3 mg/mL BSA (fatty acid-free) and saturating concen-
trations of acetoacetyl-CoA (50 μM) and NADH
(0.15 mM). Absorbance at 340 nm was measured every
minute for 5 minutes at 37C.
2.10 | Co-immunoprecipitation (co-IP)
HEK 293 SCHAD KO cells seeded in 10-cm Petri dishes
were co-transfected with 2 μg Plu-CMV-hGDH and 6 μg
of pcDNA3.1-SCHAD-V5-His variants using the calcium
phosphate method. After 48 hours of transfection, cells
were washed with PBS, incubated for 10 minutes with
1 mM disuccinimidyl glutarate and quenched for
15 minutes with 50 mM Tris, pH 7.5. Immediately after,
co-IP was performed as follows (kit from Thermo Fisher
Scientific): 6 μg of antibody were coupled to 10 μL
AminoLink Plus Coupling resin, co-IP buffer was used
for cell lysis (500 μL/plate) and washing (×7), 450 μL of
cell lysate at 2.8 μg/μL were incubated for 1 hour with
the antibody-coupled-resin, and elution (×1) was by
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NuPAGE LDS Sample buffer (Thermo Fisher Scientific),
followed by western blotting.
2.11 | Statistical analysis
The software R20 with reshape221 and multcomp22 was
used. Plots were produced using the package ggplot2.23
To evaluate differences in the enzymatic activity of the
SCHAD variants, a one-way analysis of variance
(ANOVA) and a post-hoc Dunnett's test were used. To
evaluate differences in the amount of bound GDH, a one-
sample T-test was used.
3 | RESULTS
3.1 | Selection of SCHAD variants for
functional testing
To perform a systematic functional evaluation of SCHAD
protein variants, we chose 16 missense variants present
in human populations and CHI patients (Table 1). The
population variants were selected to be distributed
throughout the domains of SCHAD, and their positions
are illustrated in Figures 1A and S1A. Specifically, nine
variants were selected from the gnomAD data set,15 most
of them having an allele frequency in the range 0.0002 to
0.005 (Table 1). We also included p.Pro86Leu, which is
the most frequent SCHAD coding variant and the only
one with an allele frequency > 0.01.27 Additionally, seven
pathogenic variants found in CHI cases were included.
Of these, six have been described in case
reports10,16,17,24-26 whereas one, p.His170Arg, has been
identified in a CHI patient via our own clinical laboratory
service (unpublished).
To characterize functional aspects of these variants
in vitro, we introduced them by site-directed mutagenesis
into plasmids pcDNA3.1 (for expression in mammalian
cells as SCHAD-V5/His fusion protein) and
pETM41-His/MBP (for expression in E. coli as MBP-
SCHAD fusion protein).
3.2 | Expression of SCHAD missense
variants in HEK293 cells
SCHAD is a ubiquitous protein that occurs as homodimer
in its functional form.18,28 To avoid the interference that
dimerization with endogenous wildtype protein could
cause in cellular studies with exogenously expressed vari-
ants, we produced a HEK293 SCHAD KO cell line using
TABLE 1 Overview of HADH variants and the studied amino acid substitutions
Nucleotide changea Amino acid variantb Exon Reference SNP ID numberc Allele frequencyd Source
c.99C > G p.Ile33Met 1 rs74428123 0.00040 gnomAD
c.100G > C p.Gly34Arg 1 rs779135938 0.00001 24
c.171C > A p.Asp57Glu 2 rs137853102 0.00001 gnomAD
c.257C > T p.Pro86Leu 2 rs4956145 0.08480 gnomAD
c.275 T > G p.Phe92Cys 3 rs61735992 0.00568 gnomAD
c.406A > G p.Lys136Glu 3 rs1262186453 0.00003 25
c.456G > T p.Gln152His 4 rs1051519 0.00175 gnomAD
c.509A > G p.His170Arg 4 — — Unpublishede
c.550A > T p.Ile184Phe 5 — — 26
c.562A > G p.Met188Val 5 — — 16
c.614G > C p.Gly205Ala 5 rs144699575 0.00023 gnomAD
c.643C > A p.Pro215Thr 6 rs140413151 0.00184 gnomAD
c.662G > A p.Arg221His 6 rs76476980 0.00117 gnomAD
c.773C > T p.Pro258Leu 7 rs137853103 — 10
c.881A > G p.Asn294Ser 8 rs36030668 0.00235 gnomAD
c.907G > A p.Gly303Ser 8 rs201772964 0.00004 17
aAccording to NCBI reference sequence NM_005327.4.
bPredicted amino acid change. Notation according to NCBI reference sequence NP_005318.3.
cAccording to the Single Nucleotide Polymorphism Database (dbSNP) (https://www.ncbi.nlm.nih.gov).
dAccording to the gnomAD database (http://gnomad.broadinstitute.org).15
eUnpublished patient from own clinical laboratory service.
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CRISPR-Cas9 targeted genome editing. Disruption of
exon 1 of the HADH gene was verified through DNA
sequencing of selected colonies (Figure S2). Knockout at
the protein level was confirmed through western blotting
using different anti-SCHAD antibodies (Figure 1B). A
band of the expected molecular mass for SCHAD
(~34 kDa) was observed only for the lysates of HEK293
WT cells, and not for SCHAD KO cells.
We then tested expression of the SCHAD variants by
transiently transfecting the plasmids into HEK293
SCHAD KO cells. Figure 1C shows selected variants in
HEK293 SCHAD KO cells to summarize the most rele-
vant findings, whereas Figure S3 presents all 16 variants
expressed in both HEK293 WT and SCHAD KO cells.
Analysis of the cellular lysates by western blotting, using
an anti-V5 antibody (Figure 1C) or an anti-SCHAD anti-
body (Figure S3), revealed a band of the expected molec-
ular mass (~37 kDa) for the WT-V5/His fusion protein.
Most missense variants exhibited the same size and
expression levels as the WT protein. The five exceptions
were p.Gly34Arg, p.Phe92Cys, p.Ile184Phe, p.Pro258Leu,
and p.Gly303Ser. The p.Phe92Cys variant, found in the
gnomAD dataset, displayed slower electrophoretic mobil-
ity than the WT protein, but had the same expression
level. The four other variants, all CHI-associated, were
consistently expressed at reduced levels. This reduction
was more pronounced for p.Gly34Arg, p.Ile184Phe,
and p.Pro258Leu than for the p.Gly303Ser variant.
However, CHI variants p.Lys136Glu, p.His170Arg, and
p.Met188Val appeared similar to the WT protein and the
remaining population variants. All 16 variants yielded
the same expression pattern in normal HEK293 (WT) as
in the SCHAD KO cell line (Figure S3).
Next, we evaluated the expression and subcellular
localization of the variants by immunofluorescence of
transiently transfected KO cells. Figure 2 exemplifies
how variants exhibiting reduced protein levels in
Figure 1C, such as p.Pro258Leu and p.Gly303Ser, also
resulted in lower amounts of SCHAD-V5 when directly
visualized in the cells. Images of the other variants are
presented in Figure S4. For variants with lower protein
levels, we did not observe a uniform overall reduction in
SCHAD levels within the expressing cells. A few cells dis-
played a fluorescence pattern comparable to that of WT-
transfected cells, while most cells showed from very low
to undetectable SCHAD levels.
By confocal microscopy, we found that all variants
were correctly targeted to the mitochondria as shown by
co-localization of SCHAD-V5 with a mitochondrial-
specific stain (Figure S5).
FIGURE 1 Location of the studied missense variants in the SCHAD protein, construction of SCHAD-deficient HEK293 cells, and
expression of selected variants in these cells. A, SCHAD has three functional domains: the mitochondrial import signal (MIS; green), the
NAD-binding domain (blue) and the dimerization domain (yellow). Protein variants of unknown significance found in populations are in
black, while pathogenic variants found in CHI patients are displayed in red. Notation is according to the reference protein sequence
NP_005318.3. For simplicity, the prefix “p.” of the amino acid variants is not included in this and the other figures. B, Western blot of cell
lysates from HEK293 cells expressing (wildtype, WT) and not expressing (knockout, KO) SCHAD protein. Membranes were probed with two
different anti-SCHAD antibodies (#1, GeneTex; #2, Novus Biologicals). C, Western blot of whole-cell lysates of HEK293 SCHAD KO cells
transfected with the indicated variants. One μg of protein was loaded in each lane, and the SCHAD variants were detected with anti-V5
antibody. A representative image of three experiments is shown. An anti-β-tubulin antibody was used for monitoring the loading in B and
C. EV = empty vector
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3.3 | Translation and protein
degradation of SCHAD variants with
reduced protein levels
To further test expression of variants p.Gly34Arg,
p.Ile184Phe, p.Pro258Leu, and p.Gly303Ser, that is, those
displaying low protein levels in HEK293 cells, we used a
cell-free expression system. Equal amounts of the
plasmids were incubated with the cell-free expression
reaction mix followed by western blotting. In stark con-
trast to the results obtained with transfected cells, these
four variants now displayed similar protein levels to WT
SCHAD (Figure 3A). This confirmed that the plasmids
were fully functional with protein synthesis being as effi-
cient as from the WT plasmid. Moreover, this observation
hinted at the activity of a cellular quality control
FIGURE 2 Expression of selected
SCHAD variants in HEK293 SCHAD
KO cells as determined by
immunofluorescence. The cells were
transiently transfected with the
indicated V5-tagged SCHAD variants,
fixed 48 hours-post transfection, stained
using anti-V5 primary antibody and
fluorescent anti-mouse IgG secondary
antibody (green), and counterstained
with DAPI (blue). Images are
representative fields from two
experiments, each with two technical
replicates (×200). WT = wildtype,
EV = empty vector
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mechanism, not present in the cell-free expression system,
as explanation for the low variant levels in HEK293 cells.
To investigate whether the four variants were
degraded by the ubiquitin-proteasome system, we blocked
this pathway in transfected cells by using the proteasome
inhibitor MG132. Figure 3B demonstrates that the
variants p.Gly34Arg, p.Ile184Phe, and p.Pro258Leu
exhibited clearly increased protein levels after 24 hours of
MG132 treatment, suggesting that proteasomal degrada-
tion is of importance for their instability. There was also
a certain effect on the level of p.Gly303Ser, an increase
that was confirmed in two additional, independent
experiments.
3.4 | Enzymatic activity of purified
SCHAD variants
Although enzymatic activity of SCHAD can be measured
in cell and tissue lysates,3 we opted for using purified
protein due to the greater flexibility of the assay and full
control over the amount of SCHAD tested. Even though
we were able to express all variants in E. coli cells, the
purification efficiency differed considerably from variant
to variant (Figure S6 and data not shown). In fact, the
levels of p.Gly34Arg, p.Phe92Cys, and p.Ile184Phe were
undetectable at the end of the SEC purification step and
therefore no further work was performed on them. Nota-
bly, for all variants we employed a purification protocol
optimized for WT SCHAD. Thus, none of the conditions
were adjusted to the individual characteristics of any spe-
cific variant as an attempt to improve the yield.
We assessed the identity and purity of the samples by
SDS-PAGE, western blotting and Coomassie staining. For
all purified variants, a band around 75 kDa was detected
by anti-SCHAD (Figure 4A) and anti-His (data not
shown) antibodies. This agrees with the predicted molec-
ular mass of ~77 kDa for MBP-SCHAD. Coomassie
staining revealed a few additional, weak bands of higher
molecular mass and unknown identity in all cases
FIGURE 3 Expression of
unstable SCHAD variants in a
cell-free system and in HEK293
cells treated with a proteasome
inhibitor. A, Equal amounts of
the vectors expressing the
indicated variants were
incubated with the cell-free
expression master mix for
90 minutes. Three microliters of
each reaction were analyzed by
western blot using an anti-V5
antibody. WT = wildtype,
EV = empty vector. B, Twenty-
four hours after transfection
with the indicated variants,
HEK293 SCHAD KO cells were
treated with 5 μM MG132 or
only DMSO for the specified
times. To be able to visualize the
unstable variants, we loaded five
times the amount of whole-cell
lysate (5 μg) per well than
loaded in Figure 1C. The blots
were analyzed by anti-V5
antibody, whereas anti-β-tubulin
and anti-β-catenin antibodies
were used for monitoring the
loading and controlling the
efficiency of MG132 treatment,
respectively
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(Figure S7A). Some variants, most notably p.Ile33Met,
exhibited additional bands of lower molecular weight.
To test if recombinant MBP-SCHAD was purified in
the functional dimeric form, we estimated the molecular
mass of purified MBP-SCHAD WT by SEC-MALS
(Figure S7B). While the predicted monomeric molecular
mass was ~77 kDa, the calculated value by SEC-MALS
analysis was ~168 kDa. This indicated that MBP-SCHAD
WT was purified in the dimeric form. As the missense
variants all eluted at the same rate as WT SCHAD
(Figure S6), we expected them to be purified as
dimers, too.
Next, we assessed the enzymatic activity of the vari-
ants in saturating conditions of substrate and co-factor
(Vmax). MBP-SCHAD WT exhibited Vmax = 181
± 3 μmol/min/mg (Figure 4B). Variants found in patients
all showed reduced activity: p.His170Arg, p.Pro258Leu,
and p.Gly303Ser had severely reduced Vmax (<10 μmol/
min/mg), while p.Lys136Glu (127 ± 8 μmol/min/mg)
and p.Met188Val (132 ± 29 μmol/min/mg) displayed a
smaller, but still significant, reduction. Interestingly, the
population variant p.Pro215Thr had a slight increase in
enzymatic activity (211 ± 5 μmol/min/mg).
3.5 | Interaction of pathogenic SCHAD
variants with GDH
We were therefore left with principally two classes of
SCHAD pathogenic variants, one with severely reduced
cellular amounts of protein and another with impaired
enzymatic activity in the presence of normal protein
levels. The variants of the latter class might still have the
capacity to inhibit GDH, thereby carrying out normal
FIGURE 4 Purified recombinant
MBP-SCHAD variants from E. coli and
their enzymatic activity. A, Western blot
of all successfully purified variants.
Purified protein samples (0.3 μg) were
analyzed using the Abmart anti-SCHAD
antibody. B, The enzymatic activity of
the purified variants was tested on three
different days, each time with three
measurements. Each dot represents the
mean of a triplicate measurement and
the horizontal lines show the overall
mean. *P < .05, ***P < .001
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SCHAD function in insulin secretion. We therefore
evaluated the ability of the variants of the second class
(p.Lys136Glu, p.His170Arg, and p.Met188Val) to bind
GDH by using co-IP (Figures 5 and S8). We co-transfected
HEK293 SCHAD KO cells with GDH and the SCHAD
variant to be tested, and then treated the cells with a
crosslinking reagent before cell lysis and co-IP. This
ensured that we captured protein interactions within the
mitochondria. The set-up was validated by including a
SCHAD variant (Δ2-12) lacking the mitochondrial import
signal and therefore unable to locate with GDH inside the
mitochondria. The positive control (WT SCHAD) and all
negative controls (EV, Δ2-12, IgG) behaved as intended.
Somewhat unexpectedly, GDH was still able to co-IP with
the three pathogenic SCHAD variants (Figure 5A, B).
Nevertheless, the GDH levels were lower for the missense
variants than for WT SCHAD in eight of nine indepen-
dent Co-IPs tests performed (Figure 5C), although for
each variant the reduction did not quite reach statistical
significance when assessed separately.
4 | DISCUSSION
We here, for the first time, present a concerted functional
assessment of naturally occurring SCHAD missense vari-
ants. We have evaluated protein expression, intracellular
localization, enzymatic activity and GDH interaction. A
strength of our study is that we used a cell line devoid of
the SCHAD protein. Because this protein naturally forms
dimers,18,28 our approach allowed the functional testing
of SCHAD variants without the interference of endoge-
nous protein.
All tested SCHAD missense variants from verified
CHI patients displayed loss-of-function phenotypes. This
is in line with the other CHI mutations in the literature
being nonsense mutations, exon deletions or mutations
that affect the splicing machinery.11 Thus, pathogenic
HADH mutations are generally predicted to result in defi-
ciency of SCHAD protein. They are recessively inherited
in all reported pedigrees (eg, References 12 and 25). One
functional HADH allele therefore provides a level of
SCHAD protein function sufficient to avoid hypoglyce-
mic episodes, and dominant-negative mutations are yet
to be described.
We found altered properties for all seven CHI-
associated SCHAD variants examined. A few case
reports of missense mutations have investigated SCHAD
protein levels and/or enzyme activity in patient fibro-
blasts. Consistent with our findings, Clayton et al10 and
Vilarinho et al17 observed low protein levels for the vari-
ants p.Pro258Leu and p.Gly303Ser, respectively, whereas
Kapoor et al16 found decreased enzymatic activity for
p.Met188Val. However, while we noted a drastically
reduced Vmax for recombinantly expressed and purified
p.Gly303Ser, Vilarinho et al17 in patient fibroblasts
FIGURE 5 Co-immunoprecipitation of GDH with selected
SCHAD variants. A,B, HEK 293 SCHAD KO cells were co-
transfected with plasmids expressing GDH and selected SCHAD-V5
variants or with GDH and an empty plasmid vector (EV). The
SCHAD variant Δ2-12 lacked the mitochondrial import signal.
Forty-eight hours post transfection, cells were treated with a
crosslinking reagent before lysis. Cell lysates (450 μL) with equal
protein concentration (Input) were incubated with either V5 or IgG
antibodies coupled to agarose beads. The proteins bound to the
antibodies/beads (IP) were separated by SDS-PAGE, and SCHAD
(GeneTex antibody) and GDH were visualized by western
blotting. C, GDH and SCHAD western blot signals were quantified
for the variants and normalized to the WT sample. The dots
represent the calculated GDH/SCHAD ratio for each replicate with
the horizontal lines showing the mean for each variant. The dashed
line corresponds to the GDH/SCHAD ratio for the wildtype co-IP
reaction
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observed a Vmax comparable to the value of healthy
controls. Still, they noted that the enzymatic function
was affected by an increased Km for binding to the co-
factor NADH.
Our results suggest that SCHAD missense variants
causing CHI exhibit at least two types of loss-of-function
phenotypes. The first group, consisting of p.Gly34Arg,
p.Ile184Phe, p.Pro258Leu, and p.Gly303Ser, displays the
most common outcome for pathogenic missense muta-
tions; that is, a decrease of the protein's half-life leading
to lower amounts in the cell.29 This can be explained by
abnormal folding of the protein such that folding inter-
mediates and/or improperly folded proteins are degraded
through a protein-quality control system. Accordingly,
we readily achieved protein expression in a cell-free
eukaryotic system, and treatment with a proteasome
inhibitor stabilized the protein levels in HEK293 cells.
The small amounts of these variants still detectable by
western blot and immunofluorescence may represent a
fraction of the synthesized protein that managed to
obtain a folded state and escape degradation before
import to the mitochondria.30
A second loss-of-function phenotype was seen for CHI
variants p.Lys136Glu, p.His170Arg, and p.Met188Val.
Here, enzymatic activity of SCHAD was clearly impacted,
but without visible affection of steady-state protein levels.
It should be pointed out, though, that biophysical stress
(such as high temperature) might have demonstrated pro-
tein instability also in this group of missense variants.
Among all CHI variants studied, p.His170Arg was
the most atypical since it is the only one located
directly in the active site of the enzyme. The His170
residue is part of the catalytic His-Glu pair and func-
tions as a catalytic base, involved in proton abstraction
from the substrate.28 In the three-dimensional confor-
mation of SCHAD, p.Lys136 and p.Met188 are both
located on the surface of the NAD-binding domain,
opposite to the catalytic site (Figure S1B). Due to the
nature of these amino acids and their location, they
could be involved in some interaction or binding, criti-
cal for proper functioning of the protein. Notably, Xu
et al18 have demonstrated that mutations distant from
the catalytic site affect the enzymatic activity of
C. elegans SCHAD by decreasing the stability of the cat-
alytic intermediate formation. Considering that in the
context of insulin regulation, SCHAD acts by inhibiting
GDH,8 we tested this particular protein-protein interac-
tion, expecting that pathogenic variants with normal
steady-state protein levels would exhibit abolished
GDH binding. However, compared with WT SCHAD
we found only a partial reduction of the GDH interac-
tion. It is therefore not obvious how these three vari-
ants result in CHI.
Of the evaluated population variants, most had
properties like that of normal SCHAD. Intriguingly, the
p.Asp57Glu variant has been identified in a patient with
fulminant hepatic failure consistent with a metabolic
disorder involving defective fatty acid oxidation. The
patient was heterozygous for p.Asp57Glu, which
occurred together with the variant p.Ala40Thr.31 In fact,
a second variant in the Asp57 residue has been identi-
fied in a patient with Reye-like syndrome (p.Asp57Gly)
who was compound heterozygous, carrying another
unique variant, p.Tyr214His.32 Possibly, these variants
could affect the function of the SCHAD protein in fatty
acid oxidation but not in insulin secretion.
Among the population variants, p.Phe92Cys stood out
by consistently migrating with slower electrophoretic
mobility. Still, its protein level was as for WT SCHAD,
and we speculate that an extra post-translational modifi-
cation involving the Cys92 residue might cause the
apparent increase in molecular mass. As p.Phe92Cys was
the only population variant that could not be purified
after E. coli expression, we cannot rule out an effect on
enzymatic function. Still, with an allele frequency of
~0.006, this variant is the second most frequent SCHAD
amino acid substitution observed in populations, and we
consider it unlikely to have a pathogenic phenotype.
There is only one common variant (allele
frequency > 0.01) of the HADH gene that results in
change of protein sequence, namely p.Pro86Leu. When
expression levels and enzyme activity of p.Pro86Leu were
evaluated in fibroblasts of heterozygous carriers, proper-
ties comparable for non-carriers were found.27 Consider-
ing that around 0.7% of the population are predicted to
be homozygous for this SNP (based on allele frequency of
~0.085 according to the gnomAD database), it was inter-
esting to test the functional effects of this variant without
any interference of the WT protein. We observed no obvi-
ous difference regarding expression or enzymatic activity
when compared with normal SCHAD.
The phenotype of SCHAD deficiency is different from
that of other genetic disorders in which genes encoding
the enzymes of fatty acid oxidation are mutated. The pro-
tein has its highest expression level in the pancreatic
β-cells,5 and it is when the islet-specific function is
disrupted that hypoglycemia ensues.6 Notably, a recent
analysis of the genetic architecture of diabetes indicated a
small, protective effect of rare variants of the HADH gene
(Figure 2c in Reference 33), an effect that might be
explained by heterozygous carriers of rare HADH vari-
ants having increased capacity for insulin secretion. A
limitation of the present study is therefore that the amino
acid substitutions were not tested in cell lines that reflect
the β-cell environment, such as INS-1 or EndoC-βH1.
Hence, it is conceivable that a variant that in the present
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study appears normal with regard to SCHAD expression
and function, still could exhibit altered properties in β-cells.
Another limitation is that we included only one of the
four SCHAD variants found in patients who had no signs
of hyperinsulinism but presented with other metabolic
diseases (fulminant hepatic failure and Reye-like syn-
drome). Only the enzyme kinetics of these non-CHI vari-
ants have so far been investigated.31,32 It would have
been interesting to investigate their properties both indi-
vidually and in the combination that they appear in the
patients, comparing with the CHI-causing variants.
Finally, future studies should address whether the CHI
variants with normal protein levels are unable to inhibit
GDH despite being able to bind it, or whether these vari-
ants disturb other crucial interactions within the protein
super complex in which SCHAD is postulated to be
embedded.34 Investigations of how GDH kinetics and
protein complex formation are impacted by the normally
expressed variants may be needed to fully clarify the
mechanism of GDH activation in SCHAD-CHI.
Nevertheless, we have established a set of useful tools
for functional testing of SCHAD protein variants. This
toolkit includes a human cell line devoid of endogenous
SCHAD expression as well as a series of eukaryotic/pro-
karyotic expression plasmids with missense variants dis-
tributed over the two major protein domains. We found
no evidence that rare SCHAD amino acid substitutions
not seen in CHI patients exhibited impaired function.
This information will be of value when interpreting
HADH genetic variants revealed by high-throughput
sequencing projects and in clinical testing.
ACKNOWLEDGMENTS
We are indebted to Drs Charles Stanley and Changhong
Li at the Children's Hospital of Philadelphia, Pennsylva-
nia, USA for providing the plasmid Plu-CMV-hGDH and
for valuable discussions. We thank Dr Sven Le Moine
Bauer for assistance with statistical analyses and Dr Bjørn
Dalhus, Structural Biology Core Facility, University of
Oslo for assistance with the SEC-MALS analysis. The
authors confirm independence from the sponsors; the con-
tent of the article has not been influenced by the sponsors.
CONFLICT OF INTEREST





1. Hitomi Y, Tokunaga K. Significance of functional disease-cau-
sal/susceptible variants identified by whole-genome analyses
for the understanding of human diseases. Proc Japan Acad Ser
B. 2017;93:657-676.
2. Najmi LA, Aukrust I, Flannick J, et al. Functional investiga-
tions of HNF1A identify rare variants as risk factors for type
2 diabetes in the general population. Diabetes. 2017;66:335-346.
3. Wanders RJA, Ruiter JPN, IJlst L, Waterham HR, Houten SM.
The enzymology of mitochondrial fatty acid beta-oxidation and
its application to follow-up analysis of positive neonatal screen-
ing results. J Inherit Metab Dis. 2010;33:479-494.
4. Hardy OT, Hohmeier HE, Becker TC, et al. Functional geno-
mics of the β-cell: short-chain 3-Hydroxyacyl-coenzyme a dehy-
drogenase regulates insulin secretion independent of K+
currents. Mol Endocrinol. 2007;21:765-773.
5. Martens GA, Vervoort A, Van De Casteele M, et al. Specificity
in beta cell expression of L-3-hydroxyacyl-CoA dehydrogenase,
short chain, and potential role in down-regulating insulin
release. J Biol Chem. 2007;282:21134-21144.
6. Molven A, Hollister-Lock J, Hu J, et al. The hypoglycemic phe-
notype is islet cell-autonomous in short-chain hydroxyacyl-CoA
dehydrogenase-deficient mice. Diabetes. 2016;65:1672-1678.
7. Pepin É, Guay C, Delghingaro-Augusto V, et al. Short-chain
3-hydroxyacyl-CoA dehydrogenase is a negative regulator of
insulin secretion in response to fuel and non-fuel stimuli in
INS832/13 β-cells. J Diabetes. 2010;2:157-167.
8. Li C, Chen P, Palladino A, et al. Mechanism of hyperinsulinism
in short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
involves activation of glutamate dehydrogenase. J Biol Chem.
2010;285:31806-31818.
9. Smith HQ, Li C, Stanley CA, Smith TJ. Glutamate dehydroge-
nase, a complex enzyme at a crucial metabolic branch point.
Neurochem Res. 2019;44:117-132.
10. Clayton PT, Eaton S, Aynsley-Green A, et al. Hyperinsulinism
in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency
reveals the importance of β-oxidation in insulin secretion.
J Clin Invest. 2001;108:457-465.
11. Molven A, Helgeland G, Sandal T, Njølstad PR (2012) The
molecular genetics and pathophysiology of congenital hyperin-
sulinism caused by short-chain 3-hydroxyacyl-coA dehydroge-
nase deficiency. In: Stanley CA, De Leon DD (eds) Monogenic
Hyperinsulinemic Hypoglycemia Disorders. Frontiers in Diabetes.
Karger, Basel, pp. 137–145.
12. Molven A, Matre GE, Duran M, et al. Familial hyper-
insulinemic hypoglycemia caused by a defect in the SCHAD
enzyme of mitochondrial fatty acid oxidation. Diabetes. 2004;
53:221-227.
13. Arnoux JB, Verkarre V, Saint-Martin C, et al. Congenital
hyperinsulinism: current trends in diagnosis and therapy.
Orphanet J Rare Dis. 2011;6:1-14.
14. Stanley CA. Perspective on the genetics and diagnosis of con-
genital hyperinsulinism disorders. J Clin Endocrinol Metab.
2016;101:815-826.
15. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational con-
straint spectrum quantified from variation in 141,456 humans.
Nature. 2020;581:434-443.
16. Kapoor RR, James C, Flanagan SE, Ellard S, Eaton S,
Hussain K. 3-Hydroxyacyl-coenzyme a dehydrogenase defi-
ciency and hyperinsulinemic hypoglycemia: characterization of
a novel mutation and severe dietary protein sensitivity. J Clin
Endocrinol Metab. 2009;94:2221-2225.
12 VELASCO ET AL.
17. Vilarinho L, Sales Marques J, Rocha H, et al. Diagnosis of a
patient with a kinetic variant of medium and short-chain
3-hydroxyacyl-CoA dehydrogenase deficiency by newborn
screening. Mol Genet Metab. 2012;106:277-280.
18. Xu Y, Li H, Jin Y-H, Fan J, Sun F. Dimerization interface of
3-hydroxyacyl-CoA dehydrogenase tunes the formation of its
catalytic intermediate. PLoS One. 2014;9:e95965.
19. Artimo P, Jonnalagedda M, Arnold K, et al. ExPASy: SIB bioin-
formatics resource portal. Nucleic Acids Res. 2012;40:597-603.
20. R Core Team. R: A Language and Environment for Statistical
Computing. Vienna: R Foundation for Statistical Computing;
2017.
21. Wickham H. Reshaping data with the {reshape} package. J Stat
Softw. 2007;21:1-20.
22. Hothorn T, Bretz F, Westfall P. Simultaneous inference in gen-
eral parametric models. Biom J. 2008;50:346-363.
23. Wickham H. ggplot2: Elegant Graphics for Data Analysis.
New York: Springer-Verlag; 2016.
24. Snider KE, Becker S, Boyajian L, et al. Genotype and pheno-
type correlations in 417 children with congenital hyperinsulin-
ism. J Clin Endocrinol Metab. 2013;98:E355-E363.
25. Flanagan SE, Patch AM, Locke JM, et al. Genome-wide homozy-
gosity analysis reveals HADH mutations as a common cause of
diazoxide-responsive hyperinsulinemic-hypoglycemia in consan-
guineous pedigrees. J Clin Endocrinol Metab. 2011;96:498-502.
26. Satapathy AK, Jain V, Ellard S, Flanagan SE. Hyperinsulinemic
hypoglycemia of infancy due to novel HADH mutation in two
siblings. Indian Pediatr. 2016;53:912-913.
27. van Hove EC, Hansen T, Dekker JM, et al. The HADHSC gene
encoding short-chain L-3-hydroxyacyl-CoA dehydrogenase
(SCHAD) and type 2 diabetes susceptibility: the DAMAGE
study. Diabetes. 2006;55:3193-3196.
28. Barycki JJ, O'Brien LK, Bratt JM, et al. Biochemical characteri-
zation and crystal structure determination of human heart short
chain L-3-hydroxyacyl-CoA dehydrogenase provide insights
into catalytic mechanism. Biochemistry. 1999;38:5786-5798.
29. Gregersen N, Bross P, Jørgensen MM, Corydon TJ,
Andresen BS. Defective folding and rapid degradation of
mutant proteins is a common disease mechanism in genetic
disorders. J Inherit Metab Dis. 2000;23:441-447.
30. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P,
Perlmutter DH. A lag in intracellular degradation of mutant
α1-antitrypsin correlates with the liver disease phenotype in
homozygous PiZZ α1-antitrypsin deficiency. Proc Natl Acad
Sci. 1994;91:9014-9018.
31. O'Brien LK, Rinaldo P, Sims HF, et al. Fulminant hepatic fail-
ure associated with mutations in the medium and short chain
L-3-hydroxyacyl-CoA dehydrogenase gene. J Inherit Metab Dis.
2000;23:127.
32. Bennett MJ, Russell LK, Tokunaga C, et al. Reye-like syndrome
resulting from novel missense mutations in mitochondrial
medium- and short-chain L-3-hydroxy-acyl-CoA dehydroge-
nase. Mol Genet Metab. 2006;89:74-79.
33. Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic
architecture of type 2 diabetes. Nature. 2016;536:41-47.
34. Narayan SB, Master SR, Sireci AN, et al. Short-chain
3-hydroxyacyl-coenzyme a dehydrogenase associates with a
protein super-complex integrating multiple metabolic path-
ways. PLoS One. 2012;7:e35048.
SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of this
article.
How to cite this article: Velasco K, St-Louis JL,
Hovland HN, et al. Functional evaluation of 16
SCHAD missense variants: Only amino acid
substitutions causing congenital hyperinsulinism
of infancy lead to loss-of-function phenotypes in
vitro. J Inherit Metab Dis. 2020;1–13. https://doi.
org/10.1002/jimd.12309
VELASCO ET AL. 13
Supplementary Figure 1 
 
 
Supplementary Figure 1. Location of the studied missense variants in the 3D representation of 
the SCHAD protein structure. The three functional domains are colored in one of the sub-units of 
the SCHAD dimer: the mitochondrial import signal in green, the NAD-binding domain in blue and the 
dimerization domain in yellow. The second subunit is colored in grey. (A) Representation showing 
secondary structure elements and the location of the altered amino acids in the studied variants 
(variants of unknown significance in black and pathogenic variants in red). (B) Surface representation 
of the same structure from two different angles, showing that the amino acids Lys136 and Met188 are 
exposed on the surface, while His170 is buried in the catalytic site. Image of PDB ID 3RQS (Kuzin et 
al. 2011) created with Chimera (Pettersen et al. 2004). 
References: 
Kuzin A, Su M, Seetharaman J, et al (2011) Northeast Structural Genomics Consortium Target HR487. doi: 10.2210/pdb3RQS/pdb 
Pettersen EF, Goddard TD, Huang CC, et al (2004) UCSF Chimera - A visualization system for exploratory research and analysis. J 
Comput Chem 25:1605–1612 





Supplementary Figure 2. Confirmation of CRISPR-Cas9-mediated disruption of SCHAD 
expression in HEK293 cells. DNA sequencing revealed an insertion early in the exon 1 coding 
sequence (the nucleotide A highlighted by a red square) in the HADH gene. Wildtype DNA and protein 
sequence are shown on top of the panel. 
  












Supplementary Figure 3. Expression of all studied SCHAD variants in HEK293 wild type (WT) 
and SCHAD knockout (KO) cells. Western blots of whole-cell lysates from HEK293 WT and 
SCHAD KO cells transfected with the indicated variants are shown. One g of protein was loaded in 
each lane. SCHAD was detected with anti-SCHAD (Atlas) and anti-V5 antibodies, the latter being 
specific for exogenous SCHAD. An anti-β-tubulin antibody was used for monitoring the loading. Note 
that endogenous SCHAD is present only in the WT cells (band around 34 kDa). 
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Supplementary Figure 4. Expression of SCHAD variants in HEK293 SCHAD KO cells as 
determined by immunofluorescence. The variants are those not shown in Figure 3. The cells were 
transiently transfected with the indicated SCHAD variants (V5-tagged), fixed 48 hours post-
transfection, stained using anti-V5 primary antibody and fluorescent anti-mouse IgG secondary 
antibody (green), and counterstained with DAPI (blue). Images are representative fields from two 
experiments, each with two technical replicates (x200). 
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Supplementary Figure 5. Intracellular localization of SCHAD variants in HEK293 SCHAD KO 
cells. Cells were transiently transfected with the indicated SCHAD variants (V5-tagged). Forty-eight 
hours post-transfection the cells were incubated with a mitochondrial stain (MitoTracker, red), fixed, 
stained using anti-V5 primary antibody and fluorescent anti-mouse IgG secondary antibody (green), 
and counterstained with DAPI (blue). Images show representative cells from two experiments, each 
with two technical replicates. (x1000). EV= empty vector.  




















Supplementary Figure 6. Size exclusion chromatography (SEC) elution profiles of purified 
SCHAD variants. Each protein variant was expressed in E. coli BL21 (DE3) cells and purified by 
immobilized metal affinity chromatography. All protein from the first purification step was further 
processed by SEC in a Superdex 200 16/60 column. In every graph, the red line corresponds to the 
elution profile of the named variant compared to the profile of the WT protein (black line). Dimeric 
MBP-SCHAD eluted in the volume between 80-90 ml (arrow). The second peak (after 90 ml) 
corresponded to other proteins of lower molecular mass as analyzed by SDS-PAGE and western blot 
(data not shown). Although the absorbance values where MBP-SCHAD is expected to elute, are very 
low for the first three variants (p.Ile33Met, p.Asp57Glu and p.Pro86Leu), we were able to detect the 
protein by SDS-PAGE and to recover a sufficient amount for the enzymatic assays. We could not 
detect or recover any protein after the final purification step for the p.Gly34Arg, p.Phe92Cys and 
p.Ile184Phe variants (data not shown). Each purification profile is one representative image from 2-3 
purification attempts. 
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Supplementary  Figure 7.  Purification  of  recombinant  MBP-SCHAD variants from E. coli. 
(A) All successfully purified SCHAD variants (0.5 g) were analyzed by SDS-PAGE and Coomassie 
staining. (B) Molecular mass calculation based on SEC-MALS analysis for MBP-SCHAD WT. The 
red line represents the refractive index trace from an in-line Superdex 200 HR 10/30 column. The 
black line corresponds to the molecular mass distribution as determined by MALS with an estimated 
molecular mass value of  168 kDa (predicted value is ~ 154 kDa). 
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Supplementary Figure 8. Full images of western blot membranes presented in main Figure 5. 
(A) Wildtype SCHAD protein (WT), variant p.Lys136Glu, a SCHAD variant lacking the 
mitochondrial import signal (Δ2-12), and empty plasmid vector (EV). (B) WT SCHAD and variants 
p.His170Arg, p.Met186Val and Δ2-12. HEK 293 SCHAD KO cells were co-transfected with plasmids 
expressing GDH and the selected V5-tagged SCHAD variant. Forty-eight hours after transfection, cells 
were treated with a crosslinking reagent before lysis. Cell lysates (450 µl) with equal protein 
concentration (Input) were incubated with either V5 or IgG antibodies coupled to agarose beads. The 
proteins bound to the antibodies/beads (IP) were separated by SDS-PAGE, and SCHAD (GeneTex 
antibody) and GDH were visualized by western blot. Representative images of three experiments with 
each variant are shown. 
 




















Supplementary Table 1. Primers used to introduce the studied variants in the HADH sequence 
by site-directed mutagenesis. Primers were designed according to manufacturer instructions using 








Sequences of mutagenesis primers 
c.99C>G p.Ile33Met F: 5'-gcacgtgacggtcatgggcggcgg-3' 
R:5'-ccgccgcccatgaccgtcacgtgc-3' 
c.100G>C p.Gly34Arg F: 5'- cagcccgccgcggatgaccgtca-3'  
R: 5'-tgacggtcatccgcggcgggctg-3' 
c.171C>A p.Asp57Glu F: 5'-acagtagtgttggtagaacagacagaggacatcct-3' 
R: 5'-aggatgtcctctgtctgttctaccaacactactgt-3' 
c.257C>T p.Pro86Leu F: 5'-gaagtttgcagaaaaccttaaggccggcgatgaa-3' 
R: 5'-ttcatcgccggccttaaggttttctgcaaacttc-3' 
c.275T>G p.Phe92Cys F: 5'-ccctaaggccggcgatgaatgtgtggagaaga-3' 
R: 5'-tcttctccacacattcatcgccggccttaggg-3' 
c.406A>G p.Lys136Glu F: 5'-tatgttcagcagcaaactcgtccagccttttgaagag-3'  
R: 5'-cttctccagtcttcttgctgaacttgttctctgctac-3' 
c.456G>T p.Gln152His F: 5'-cattagctatgcttgtaatatgcaaggaggaagtgttgc-3' 
R: 5'-gcaacacttcctccttgcatattacaagcatagctaatg-3' 
c.509A>G p.His170Arg F: 5'-cgattcgctggcctccgtttcttcaacccagtg-3' 
R: 5'-cactgggttgaagaaacggaggccagcgaatcg-3' 
c.550A>T p. Ile184Phe F: 5'-ctggtcattggtgttttaaagacctccacaagtttcatg-3' 
R: 5'-catgaaacttgtggaggtctttaaaacaccaatgaccag-3' 
c.562A>G p.Met188Val F: 5'-cttctggctggtcactggtgttttaatgacctcc-3' 
R: 5'-ggaggtcattaaaacaccagtgaccagccagaag-3' 
c.614G>C p.Gly205Ala F: 5'-actttagcaaagccctagcaaagcatcctgtttcttg-3' 
R: 5'-caagaaacaggatgctttgctagggctttgctaaagt-3' 
c.643C>A p.Pro215Thr F:5'-ggttcacaataaacccagtagtgtccttgcaagaaac-3' 
R:5'-gtttcttgcaaggacactactgggtttattgtgaacc-3' 
c.662G>A p.Arg221His F: 5'-tgggtttattgtgaaccacctcctggttccatacc-3' 
R: 5'-ggtatggaaccaggaggtggttcacaataaaccca-3' 
c.773C>T p.Pro258Leu F: 5'-cggttaccccatgggcctatttgagcttctagatt-3' 
R: 5'-aatctagaagctcaaataggcccatggggtaaccg-3' 
c.881A>G p.Asn294Ser F: 5'-gctaccagcttacttaaggatgggctgggctg-3' 
R: 5'-cagcccagcccatccttaagtaagctggtagc-3' 
c.907G>A p.Gly303Ser F: 5'-gtagcagagaacaagttcagcaagaagactggagaag-3' 
R: 5'-cttctccagtcttcttgctgaacttgttctctgctac-3' 
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